



Systematic Review

Comparison of Liquid-Based Preparations with Conventional Smears in Thyroid Fine-Needle Aspirates: A Systematic Review and Meta-Analysis

Yun Jin Kang¹, Hyeon Woo Lee¹, Gulnaz Stybayeva² and Se Hwan Hwang^{3,*}

- ¹ Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University College of Medicine, Cheonan 14584, Republic of Korea; savie87@gmail.com (Y.J.K.); fawa7878@naver.com (H.W.L.)
- ² Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA; stybayeva.gulnaz@mayo.edu
- ³ Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- * Correspondence: yellobird@catholic.ac.kr; Tel.: +82-32-340-7044

Simple Summary: We compared the diagnostic accuracy of conventional smears and liquid-based preparations for detecting thyroid lesions using fine-needle aspiration cytology. We reviewed 15,861 samples from 17 studies. There was no significant difference between conventional smears and liquid-based preparations in terms of diagnostic accuracy or the proportion of inadequate smears. SurePath outperformed ThinPrep in terms of diagnostic accuracy among the liquid-based preparations. Recommendations for one method over another should take cost, feasibility, and accuracy into account, necessitating additional research.

Abstract: Background: To compare conventional smears (CSs) and liquid-based preparations (LBPs) for diagnosing thyroid malignant or suspicious lesions. Methods: Studies in the PubMed, SCOPUS, Embase, Web of Science, and Cochrane database published up to December 2023. We reviewed 17 studies, including 15,861 samples. Results: The diagnostic odds ratio (DOR) for CS was 23.6674. The area under the summary receiver operating characteristic curve (AUC) was 0.879, with sensitivity, specificity, negative predictive value, and positive predictive value of 0.8266, 0.8668, 0.8969, and 0.7841, respectively. The rate of inadequate specimens was 0.1280. For LBP, the DOR was 25.3587, with an AUC of 0.865. The sensitivity, specificity, negative predictive value, and positive predictive value were 0.8190, 0.8833, 0.8515, and 0.8562. The rate of inadequate specimens was 0.1729. For CS plus LBP, the AUC was 0.813, with a lower DOR of 9.4557 compared to individual methods. Diagnostic accuracy did not significantly differ among CS, LBP, and CS plus LBP. Subgroup analysis was used to compare ThinPrep and SurePath. The DORs were 29.1494 and 19.7734. SurePath had a significantly higher AUC. Conclusions: There was no significant difference in diagnostic accuracy or proportion of inadequate smears between CS and LBP. SurePath demonstrated higher diagnostic accuracy than ThinPrep. Recommendations for fine-needle aspiration cytology should consider cost, feasibility, and accuracy.

Keywords: thyroid gland; fine-needle aspiration biopsy; cytology; conventional smears; liquid-based preparation; meta-analysis

1. Introduction

Thyroid nodules are predominantly benign but exhibit a prevalence of \sim 4–7% in the general population [1]. Papillary thyroid carcinoma, the most frequent among malignant lesions, has been increasing in prevalence [2,3]. Due to the extensive vascularization of the thyroid, histological biopsies are challenging to perform. Consequently, fine-needle



Citation: Kang, Y.J.; Lee, H.W.; Stybayeva, G.; Hwang, S.H. Comparison of Liquid-Based Preparations with Conventional Smears in Thyroid Fine-Needle Aspirates: A Systematic Review and Meta-Analysis. *Cancers* **2024**, *16*, 751. https://doi.org/10.3390/ cancers16040751

Academic Editor: Vasko Vasyl

Received: 3 January 2024 Revised: 30 January 2024 Accepted: 5 February 2024 Published: 11 February 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). aspiration cytology (FNAC) has become the primary minimally invasive diagnostic method for these nodules [4–6].

Conventional smear (CS) is a common method of FNAC for thyroid lesions [7]. It is recognized for its simplicity and convenience [8]. Furthermore, it is relatively safe, repeatable, and low risk [6,7,9,10]. However, CS can report variable results, depending on the uneven thyroid tissue samples or cytopathologist's experience [8,10,11]. Artifacts may also arise during the drying of specimens, and results can vary by technician [9]. In addition, the presence of fibrosis and cystic lesions can result in poor cellularity [8]. These limitations can lead to a ~50% increase in inadequate specimens, complicating accurate diagnoses by pathologists [12].

The liquid-based preparation (LBP) method is a novel diagnostic approach in FNAC and is extensively used for breast and salivary gland examinations [1,13,14]. Introduced in 1996 as an alternative to the traditional Papanicolaou smear, LBP aims to standardize samples by minimizing artifacts and errors inherent in CS [1,8,10,15]. Two commonly used kits are ThinPrep (Hologic, Marlborough, MA, USA) and SurePath (BD Diagnostics-TriPath Imaging, Burlington, NC, USA). LBP involves collecting aspirates in a special fixative and employing an automated machine to reduce cell debris, inflammatory cells, red blood cells, and artifacts, thus producing a uniformly distributed Papanicolaou smear slide [8,9]. Through processes such as homogenization, vacuum application, and sedimentation, it provides well-preserved sample cells against a clean background [8,10].

However, the effectiveness of LBP for diagnosing thyroid lesions, where cell cluster shape and background are crucial, remains debatable [8]. Few studies and reviews have compared CS and LBP, and many exhibit a bias toward LBP, with varied criteria for evaluating sensitivity and specificity [8,10,13,14,16–18]. We performed a comparative metaanalysis of the diagnostic accuracy and rate of inadequate smears (RISs) between CS and LBP in FNAC of malignant or suspicious thyroid lesions, incorporating the latest research. In addition, we conducted subgroup analyses comparing two common LBP kits, ThinPrep and SurePath.

2. Materials and Methods

2.1. Study Protocol and Registration

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [19] and was conducted in accordance with recommendations for optimal searches of the literature in systematic reviews within the field of surgery [20]. The study protocol was prospectively registered on the Open Science Framework (https://osf.io/zj4hv/, accessed on 11 December 2023).

2.2. Literature Search Strategy

Clinical studies were sourced from PubMed, SCOPUS, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials up to December 2023. The search terms included 'thyroid gland', 'fine-needle aspiration', 'fine-needle aspiration biopsy', 'cytology', 'cytopathology', 'conventional smear', 'direct smear', and 'liquid-based preparation'. We also reviewed the references of identified articles to ensure no relevant studies were overlooked. Two independent reviewers scrutinized all abstracts and titles for eligible studies, excluding those unrelated to the diagnosis of thyroid malignancies or suspicious lesions through cytologic examination based on fine-needle aspiration and confirmed by surgical histologic examination.

2.3. Selection Criteria

The inclusion criteria were patients undergoing fine-needle aspiration biopsy for thyroid lesions, prospective or retrospective studies, studies comparing the diagnostic accuracy of CS and LBP against surgical histologic findings, and the availability of data for sensitivity and specificity analysis. The exclusion criteria included case reports, review articles, studies on other head and neck lesions such as neck lymph nodes or neck masses, and data not applicable for assessing the diagnostic value of imaging studies. The search strategy was summarized in a flow diagram to screen studies selected for the meta-analysis (Figure 1).




Figure 1. Diagram of the selection of studies for meta-analysis.

2.4. Data Extraction and Risk of Bias Assessment

Among all studies included in the meta-analysis, studies published after 2010 evaluated thyroid malignant lesions using the Bethesda system of reporting thyroid cytopathology. Other included studies that did not use the Bethesda system of reporting thyroid cytopathology were also compared, including suspicions for malignancy, malignant, nondiagnostic, or inadequate lesions evaluated by the Bethesda system. Because the cytologic categories, except malignant lesions, were different for each included study, it was difficult to evaluate benign and atypia lesions. Therefore, it was difficult to expect malignancy risk in the different diagnostic classes, and we summarized the numbers of excluded categories (Supplementary Table S1).

Data were abstracted using standardized forms by two independent reviewers [21]. The outcomes for analysis included diagnostic accuracy (diagnostic odds ratio (DOR)), the summary receiver operating characteristic (sROC) curve, and the area under the curve (AUC) [6,9,17,22–41].

The DOR was calculated as (true positive (TP)/false positive (FP))/(false negative (FN)/true negative (TN)) to assess diagnostic accuracy with 95% confidence intervals (CIs) using random-effects models that accounted for both within- and between-study variation. The DOR values range from 0 to infinity, with higher values indicating better diagnostic performance. A value of 1 suggests that the test provides no diagnostic advantage. The sROC is preferred for meta-analyses of studies reporting sensitivity and specificity pairs. As the discriminatory power of a test increases, the sROC curve approaches the top left corner in the ROC space, where sensitivity and specificity both equal 1 (100%) [42]. The

AUC, ranging between 0 and 1, reflects test performance quality; values between 0.90 and 1.0 are considered excellent, 0.80–0.90 are good, 0.70–0.80 are fair, 0.60–0.70 are poor, and 0.50–0.60 are considered failures [43].

Data extracted from the studies included the number of patients, the correlations among scores in endoscopy and computed tomography, and TP, TN, FP, and FN for AUC and DOR calculations. The Quality Assessment of Diagnostic Accuracy Studies version 2 tool was employed to evaluate methodological quality and risk of bias [44].

2.5. Statistical Analysis and Outcome Measurements

The 'R' statistical software (Version 4.3.2) (R Foundation for Statistical Computing, Vienna, Austria) was used for meta-analysis. Homogeneity analyses employed the Q statistic to assess heterogeneity. Subgroup analyses were conducted using different types of imaging studies. Forest plots were used to depict sensitivity, specificity, and sROC curves. Begg's funnel plot and Egger's linear regression test were performed to evaluate potential publication bias.

3. Results

3.1. Search and Study Selection

In total, 17 studies, including 15,861 samples, were included in the analysis (Figure 1). The characteristics of the studies are detailed in Table 1, and the bias assessment results are given in Table 2. Egger's test was significant (p < 0.05), indicating no apparent bias in the included studies, as suggested by Begg's funnel plot (Figure 2).

Study	Design	Total Number of Patients (n)	Age of Patients (Years, Median (Range) or Mean \pm SD)	Sex (F/M)	Nationality	Comparison	Inadequate Smear (n/N)	Reference Test
Scurry 2000 [22]	Retrospective	327	48 (19–84)	189/138	Canada	Direct smear	40/109	Surgery confirmed
Scurry 2000 [22]	Retrospective	327	48 (19–84)	189/138	Canada	Thin-Prep liquid-based preparation	31/90	Surgery confirmed
Afify 2001 [23]	Retrospective	209	NA	NA	USA	Thin-Prep liquid-based preparation	26/95	Surgery confirmed
Afify 2001 [23]	Retrospective	209	NA	NA	USA	Thin-Prep liquid-based preparation	26/95	Surgery confirmed
Afify 2001 [23]	Retrospective	209	NA	NA	USA	Direct smear	9/46	Surgery confirmed
Afify 2001 [23]	Retrospective	209	NA	NA USA Direct smear		9/46	Surgery confirmed	
Cochand-Priollet 2003 [24]	Case control	50	46.9 (24–70)	36/14	France	Direct smear	10/120	Surgery confirmed
Cochand-Priollet 2003 [24]	Case control	50	46.9 (24–70)	36/14	France	Thin-Prep liquid-based preparation	27/120	Surgery confirmed
Malle 2006 [17]	Retrospective	459	NA	NA	Greece	Direct smear	8/285	Only inadequate smear checked for this study
Malle 2006 [17]	Retrospective	459	NA	NA	Greece	Thin-Prep liquid-based preparation	7/174	Only inadequate smear checked for this study
Kim 2007 [41]	Prospective	172	NA	NA	Korea	SurePathTM liquid-based cytology	16/172	Surgery confirmed
Kim 2007 [41]	Prospective	172	NA	NA	Korea	Direct smear	36/172	Surgery confirmed
Stamataki 2007 [45]	Retrospective	157	NA	NA	Greece	Thin-Prep liquid-based preparation		Surgery confirmed
Cavaliere 2008 [25]	Prospective	3875	NA	NA	Italy	Thin-Prep liquid-based preparation	1252/3875	Surgery confirmed
Cavaliere 2008 [25]	Prospective	3875	NA	NA	Italy	Direct smear	1416/3875	Surgery confirmed

Table 1. The characteristics of the included studies.

		lable 1. Com						
Study	Design	Total Number of Patients (n)	Age of Patients (Years, Median (Range) or Mean \pm SD)	Sex (F/M)	Nationality	Comparison	Inadequate Smear (n/N)	Reference Test
Jung 2008 [26]	Prospective	193	48.9 (20-81)	164/29	Korea	Direct smear	12/193	Surgery confirmed
Jung 2008 [26]	Prospective	193	48.9 (20-81)	164/29	Korea	SurePathTM liquid-based cytology	10/193	Surgery confirmed
Saleh 2008 [36]	Retrospective	126	NA	NA	USA	Direct smear	45/126	Only inadequate smear checked for this study
Saleh 2008 [36]	Retrospective	126	NA	NA	USA	Thin-Prep liquid-based preparation	40/126	Only inadequate smear checked for this study
Ardito 2010 [46]	Retrospective	353	45.8 (13–82)	267/86	Italy	Thin-Prep liquid-based preparation + Direct smear		Surgery confirmed
Geers 2010 [47]	Retrospective	178	NA	NA	Belgium	SurePath liquid-based preparation		Surgery confirmed
Luu 2010 [27]	Prospective	4101	NA	NA	USA	Thin-Prep liquid-based preparation + Direct smear	174/2000	Surgery confirmed
Luu 2010 [27]	Prospective	4101	NA	NA	USA	Thin-Prep liquid-based preparation	173/2102	Surgery confirmed
Koo 2011 [28]	Prospective	30	NA	NA	Korea	CellprepPlus liquid-based preparation	96/193	Surgery confirmed
Koo 2011 [28]	Prospective	30	NA	NA	Korea	Direct smear	32/193	Surgery confirmed
Kim 2011 [29]	Prospective	30	NA	NA	Korea	Direct smear		Surgery confirmed
Kim 2011 [29]	Prospective	30	NA	NA	Korea	SurePath liquid-based preparation		Surgery confirmed
Chang 2012 [30]	Prospective	4290	50	3662/628	Korea	Direct smear	458/1767	Surgery confirmed
Chang 2012 [30]	Prospective	4290	50	3662/628	Korea	Thin-Prep liquid-based preparation + Direct smear	318/2523	Surgery confirmed
Nagarajan 2015 [31]	Retrospective	1407	50 (7-84)	NA	USA	Direct smear	516/5169	Surgery confirmed
Nagarajan 2015 [31]	Retrospective	1407	50 (7–84)	NA	USA	Liquid-based preparation (not specified)	52/306	Surgery confirmed
Chang 2016 [48]	Retrospective	30	NA	NA	Korea	EASYPREPV liquid-based preparation	21/253	Surgery confirmed
Chang 2016 [48]	Retrospective	30	NA	NA	Korea	SurePath liquid-based preparation	15/253	Surgery confirmed
Gupta 2018 [37]	Prospective	60	NA	NA	India	Thin-Prep liquid-based preparation	2/60	Surgery confirmed
Gupta 2018 [37]	Prospective	60	NA	NA	India	Direct smear	5/60	Surgery confirmed
Kumari 2020 [32]	Prospective	100	NA	NA	India	Direct smear	10/100	Surgery confirmed
Kumari 2020 [32]	Prospective	100	NA	NA	India	SurePath liquid-based preparation	14/100	Surgery confirmed
Rufail 2020 [33]	Retrospective	584	NA	NA	USA	Direct smear	19/73	Surgery confirmed
Rufail 2020 [33]	Retrospective	584	NA	NA	USA	Thin-Prep liquid-based preparation + Direct smear	65/511	Surgery confirmed
Zhao 2020 [34]	Retrospective	221	20–76	178/43	China	Thin-Prep liquid-based preparation		Surgery confirmed

Table 1. Cont.

Study	Design	Total Number of Patients (n)	Age of Patients (Years, Median (Range) or Mean \pm SD)	Sex (F/M)	Nationality	Comparison	Inadequate Smear (n/N)	Reference Test	
Zhao 2020 [34]	Retrospective	221	20–76	178/43	China	SurePath liquid-based preparation		Surgery confirmed	
Mahajan 2021 [38]	Prospective case–control	200	21–72	170/30	India	Direct smear	7/200	Surgery confirmed	
Mahajan 2021 [38]	Prospective case-control	200	21–72	170/30	India	SurePath liquid-based preparation	36/200	Surgery confirmed	
Ucak 2021 [35]	Retrospective	879	46.7 (18–82)	700/179	Turkey	Liquid-based preparation (not specified)		Surgery confirmed	
Ucak 2021 [35]	Retrospective	879	46.7 (18-82)	700/179	Turkey	Direct smear		Surgery confirmed	
Ucak 2021 [35]	Retrospective	879	46.7 (18–82)	700/179	Turkey	Liquid-based preparation (not specified) + Direct smear		Surgery confirmed	
Alam 2022 [39]	Prospective	131	33.15 ± 12.38	NA	India	SurePath liquid-based preparation	22/131	Surgery confirmed	
Alam 2022 [39]	Prospective	131	33.15 ± 12.38	NA	India	Direct smear	9/131	Surgery confirmed	
Sayer 2022 [40]	Retrospective	572	54.3 ± 10.16	446/126	Turkey	Direct smear	63/266	Surgery confirmed	
Sayer 2022 [40]	Retrospective	572	54.3 ± 10.16	446/126	Turkey	SurePath liquid-based preparation	49/359	Surgery confirmed	
Erdoğan 2023 [49]	Retrospective	4855	4855	41-60	4069/786	Turkey	SurePath liquid-based preparation	324/2898	Surgery confirmed
Erdoğan 2023 [49]	Retrospective	4855	41-60	4069/786	Turkey	Cytospin liquid-based cytology	250/957	Surgery confirmed	
Maurya 2023 [9]	Prospective, observational	250	12–72	224/26	India	SurePath liquid-based preparation	39/250	Surgery confirmed	
Maurya 2023 [9]	Prospective, observational	250	12–72	224/26	India	Direct smear	13/250	Surgery confirmed	
Xiong 2023 [6]	Retrospective	337	21–71	266/71	China	SurePath liquid-based preparation		Surgery confirmed	
Xiong 2023 [6]	Retrospective	337	21–71	266/71	China	Direct smear		Surgery confirmed	

Table 1. Cont.

NA; not available.


Table 2. Individual non-randomized controlled trial methodological quality.

Study		Selec	tion ^a		Comparability ^b		Exposure ^c			
Study	1	2	3	4	5A	5B	6	7	8	The Newcastle–Ottawa Scale
Scurry 2000 [22]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Afify 2001 [23]	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	6
Cochand-Priollet 2003 [24]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Malle 2006 [17]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Kim 2007 [41]	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	6
Cavaliere 2008 [25]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Jung 2008 [26]	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	6
Saleh 2008 [36]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	6
Luu 2010 [27]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Koo 2011 [28]	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	7
Kim 2011 [29]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	6
Chang 2012 [30]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7


<u> </u>		Selec	tion ^a		Compar	E	xposure	e c		
Study	1	2	3	4	5A	5B	6	7	8	The Newcastle–Ottawa Scale
Nagarajan 2015 [31]	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	6
Gupta 2018 [37]	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	7
Kumari 2020 [32]	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	6
Rufail 2020 [33]	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	7
Zhao 2020 [34]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Ucak 2021 [35]	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	7
Mahajan 2021 [38]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Alam 2022 [39]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	7
Sayer 2022 [40]	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	6
Maurya 2023 [9]	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	7
Xiong 2023 [6]	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	6


Table 2. Cont.

A star rating system was used to indicate the quality of a study, with a maximum of nine stars. A study could be awarded a maximum of one star for each numbered item within the selection and exposure categories. ^a: Selection (4 items): adequacy of case definition; representativeness of the cases; selection of controls; and definition of controls. ^b: Comparability (1 item): comparability of cases and controls on the basis of the design or analysis. ^c: Exposure (3 items): ascertainment of exposure; same method of ascertainment for cases and controls; and non-response rate (same rate for both groups).












Figure 2. Begg's funnel plot. (**a**) sensitivity, (**b**) specificity, (**c**) negative predictive value, (**d**) diagnostic odd ratios, and (**e**) rate of inadequate specimens.

3.2. Diagnostic Accuracy

In the case of CS, the DOR was 23.6674 (95% CI [13.4718; 41.5794]; $I^2 = 82.6\%$) (Figure 3). The AUC was 0.879 (Figure 4). Sensitivity, specificity, and negative predictive value of CS were 0.8266 (95% CI [0.7498; 0.8835]; $I^2 = 87.2\%$), 0.8668 (95% CI [0.7721; 0.9259]; $I^2 = 96.1\%$), and 0.8969 (95% CI [0.7805; 0.9552]; $I^2 = 97.6\%$), respectively. The RIS was 0.1280 (95% CI [0.0865; 0.1853]; $I^2 = 98.5\%$).




Figure 3. Cont.

Study	Events	Total	Proportion	95%-CI
g = direct smear			1	
Scurry 2000	47	59	0.797	[0.672; 0.890]
Afity 2001	10	14		[0.419; 0.916]
Cochand?Priollet 2003	20	30		[0.472; 0.827]
Kim 2007 Cavaliere 2008	7 3784	10 3853		[0.348; 0.933] [0.977; 0.986]
Jung 2008	3/04	4		[0.194; 0.994]
Koo 2011	11	11		[0.715; 1.000]
Kim 2011	9	16		[0.299; 0.802]
Chang 2012	68	106		[0.543; 0.732]
Nagarajan 2015	701	805	0.871	
Kumari 2020 Rufail 2020	10	10	1,000	[0.692; 1.000]
Ucak 2021	400	534		[0.710; 0.785]
Maurya 2023	70	74		[0.867; 0.985]
Xiong 2023	357	394		[0.873; 0.933]
Random effects model		5933	0.867	[0.772; 0.926]
Heterogeneity: $I^2 = 97\%$, τ^2	= 1.2545,	p < 0.01		
g = liquid-based cytolog				
Scurry 2000	54	66	0.818	[0.704; 0.902]
Afity 2001	15	19		[0.544; 0.939]
Cochand?Priollet 2003	15	25		[0.387; 0.789]
Kim 2007	12	13	0.923	
Cavaliere 2008 Jung 2008	3784	3853	0.982	
Luu 2010	302	334		[0.867; 0.934]
Koo 2011	13	13		[0.753; 1.000]
Kim 2011	10	16	0.625	[0.354; 0.848]
Nagarajan 2015	26	28	.929	[0.765; 0.991]
Kumari 2020	10	10		[0.692; 1.000]
Zhao 2020	21	21		[0.839; 1.000]
Zhao 2020 Ucak 2021	10 392	10 534		[0.692; 1.000]
Maurya 2023	68	74		[0.832; 0.970]
Xiong 2023	35	394 -		[0.063; 0.121]
Random effects model		5414		[0.735; 0.954]
Heterogeneity: $I^2 = 98\%$, τ^2	= 3.2881,	p < 0.01		
g = liquid-based cytolog Luu 2010	300	342	0.977	[0.838; 0.910]
Chang 2012	45	80		[0.447; 0.673]
Rufail 2020	40	80		[0.386; 0.614]
Ucak 2021	445	534		[0.799; 0.864]
Random effects model		1036		[0.537; 0.859]
Heterogeneity: $l^2 = 96\%$, τ^2	= 0.6814,	p < 0.01		
A CONTRACTOR OF A		100	1	
Random effects model		12383	0.857	[0.779; 0.911]
Heterogeneity: $l^2 = 98\%$, τ^2	= 2.0547,	p < 0.01	D ₀ 2 ₁₇₎ 0.4 0.6 0.8 1	
Test for subgroup difference	es: 72 = 3	.49, 01 = 2 (p		
			(b)	
Study	Even	ts Total	(b) Proportion	95%-CI
Study	Even	ts Total	(b) Proportion	95%-CI
g = direct smear			Proportion	
g = direct smear Scurry 2000	4	47 59	Proportion 0.797	[0.672; 0.890]
g = direct smear Scurry 2000 Afify 2001	4	47 59 10 13	Proportion 0.797 0.769	[0.672; 0.890] [0.462; 0.950]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003	4	47 59 10 13 20 22	Proportion 0.797 0.769 0.909 0.909	[0.672; 0.890] [0.462; 0.950] [0.708; 0.989]
g = direct smear Scurry 2000 Afify 2001	4	47 59 10 13 20 22 7 11	Proportion 0.797 0.769	[0.672; 0.890] [0.462; 0.950] [0.708; 0.989]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007	4	47 59 10 13 20 22 7 11	Proportion 0.797 0.769 0.909 0.636	[0.672; 0.890] [0.462; 0.950] [0.708; 0.989] [0.308; 0.891] [0.997; 1.000]
g = direct smear Scurry 2000 Affy 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011	4 1 2 378	47 59 10 13 20 22 7 11 34 3788 3 6 11 11	Proportion 0.797 0.769 0.909 0.636 0.999 0.500 1.000	[0.672; 0.890] [0.462; 0.950] [0.708; 0.989] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011	4 1 2 378 1	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9	Proportion 0.797 0.769 0.909 0.638 0.999 0.500 0.90 0.9	[0.672; 0.890] [0.462; 0.950] [0.708; 0.989] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000]
g = direct smear Scurry 2000 Afify 2001 CochandProilet 2003 Kim 2007 Cavaliere 2008 Koo 2011 Kim 2011 Chang 2012	4 1 2 378 1 6	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 58 98	Proportion 0.797 0.799 0.909 0.638 0.999 0.500 0.500 0.500 0.500 0.500 0.684 0.000 0.684	[0.672; 0.890] [0.462; 0.950] [0.708; 0.889] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.593; 0.783]
g = direct smear Scury 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015	4 1 2 378 1 6 70	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 58 98 01 814	Proportion 0.797 0.769 0.909 0.636 0.999 0.500 0	[0.672; 0.890] [0.462; 0.950] [0.708; 0.989] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.593; 0.783] [0.836; 0.884]
g = direct smear Scurry 2000 Afify 2001 CochandProilet 2003 Kim 2007 Cavaliere 2008 Koo 2011 Kim 2011 Chang 2012	4 1 2 378 1 6 70 1	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 58 98	Proportion 0.797 0.799 0.909 0.638 0.999 0.500 0.500 0.500 0.500 0.500 0.684 0.000 0.684	[0.672, 0.890] [0.462, 0.950] [0.708, 0.989] [0.308, 0.891] [0.997, 1.000] [0.118, 0.882] [0.715, 1.000] [0.664, 1.000] [0.864, 0.884] [0.36, 0.884] [0.516, 0.979]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020	4 1 2 378 1 6 70 1	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 58 98 51 814 10 12 13 16	Proportion 0.797 0.769 0.909 0.638 0.999 0.500 0.000 0	$\begin{matrix} [0.672; 0.890] \\ [0.462; 0.950] \\ [0.708; 0.989] \\ [0.308; 0.891] \\ [0.997; 1.000] \\ [0.715; 1.000] \\ [0.684; 1.000] \\ [0.693; 0.783] \\ [0.836; 0.884] \\ [0.516; 0.979] \\ [0.544; 0.960] \\ [0.621; 0.887] \end{matrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023	4 1 2 378 1 6 70 1 1 40 7	47 59 10 13 20 22 7 11 3 6 11 11 9 9 58 98 51 814 10 12 13 16 00 467 70 73	Proportion 0.797 0.799 0.099 0.636 0.999 0.500 0.500 0.500 0.909 0.634 0.999 0.638 0.999 0.999 0.981 0.000 0.001 0	$\begin{matrix} [0.672, 0.890] \\ [0.462, 0.950] \\ [0.708, 0.989] \\ [0.308, 0.891] \\ [0.308, 0.891] \\ [0.178, 0.882] \\ [0.715, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 0.664] \\ [0.664, 0.979] \\ [0.516, 0.979] \\ [0.542, 0.887] \\ [0.885, 0.991] \end{matrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023	4 1 2 378 1 6 70 1 1 1 40 7 35	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 38 98 11 11 10 12 13 16 00 467 70 73 367 469	Proportion 0.797 0.769 0.999 0.636 0.999 0.500 0	$\begin{matrix} [0.672, 0.890] \\ [0.462, 0.950] \\ [0.708, 0.989] \\ [0.308, 0.891] \\ [0.971, 1000] \\ [0.118, 0.882] \\ [0.715, 1.000] \\ [0.633, 0.783] \\ [0.533, 0.783] \\ [0.336, 0.884] \\ [0.514, 0.970] \\ [0.544, 0.960] \\ [0.544, 0.960] \\ [0.542, 0.987] \\ [0.720, 0.799] \end{matrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Xiong 2023 Random effects mode	4 1 2 378 1 6 70 1 1 40 7 7 35	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 98 98 11 814 10 12 13 16 10 467 70 73 57 469 5868 5869	Proportion 0.797 0.769 0.999 0.636 0.999 0.0500 1.000 0.634 0.857 0.857 0.857 0.857 0.857 0.857 0.857 0.857 0.857 0.761	$\begin{matrix} [0.672, 0.890] \\ [0.462, 0.950] \\ [0.708, 0.989] \\ [0.308, 0.891] \\ [0.308, 0.891] \\ [0.118, 0.882] \\ [0.715, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 0.783] \\ [0.363, 0.884] \\ [0.516, 0.979] \\ [0.544, 0.960] \\ [0.821, 0.887] \\ [0.885, 0.991] \end{matrix}$
g = direct smear Scurry 2000 Afity 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects mode Heterogenetity. I ² = 96%,	378 378 1 6 70 1 40 7 35 1 $\tau^{2} = 2.60$	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 98 98 11 814 10 12 13 16 10 467 70 73 57 469 5868 5869	Proportion 0.797 0.769 0.999 0.636 0.999 0.0500 1.000 0.634 0.857 0.857 0.857 0.857 0.857 0.857 0.857 0.857 0.857 0.761	$\begin{matrix} [0.672, 0.890] \\ [0.462, 0.950] \\ [0.708, 0.989] \\ [0.308, 0.891] \\ [0.971, 1000] \\ [0.118, 0.882] \\ [0.715, 1.000] \\ [0.633, 0.783] \\ [0.533, 0.783] \\ [0.336, 0.884] \\ [0.514, 0.970] \\ [0.544, 0.960] \\ [0.544, 0.960] \\ [0.542, 0.987] \\ [0.720, 0.799] \end{matrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Xiong 2023 Random effects mode Heterogeneity: J ² = 98%, g = liquid-based cytol	$ \begin{array}{c} 4 \\ 1 \\ 2 \\ 378 \\ 6 \\ 70 \\ 1 \\ 40 \\ 7 \\ 35 \\ 1 \\ 40 \\ 7 \\ 2 \\ 2 \\ 2 \\ 9 \\ 9 \\ 9 \\ 9 \\ 9 \\ 9 \\ 9 \\ 9 \\ 9 \\ 9$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.796 0.999 0.500 0.686 0.684 0.881 0.881 0.882 0	$\begin{matrix} [0.672, 0.890] \\ [0.462, 0.950] \\ [0.708, 0.989] \\ [0.308, 0.891] \\ [0.997, 1.000] \\ [0.118, 0.882] \\ [0.715, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 1.000] \\ [0.664, 0.979] \\ [0.516, 0.973] \\ [0.516, 0.973] \\ [0.516, 0.973] \\ [0.516, 0.973] \\ [0.516, 0.973] \\ [0.521, 0.887] \\ [0.885, 0.991] \\ [0.780, 0.955] \end{matrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects mode Heterogeneity: / ² = 98%, g = liquid-based cytol Scurry 2000	$\begin{array}{c} 4\\ 2\\ 378\\ 1\\ 6\\ 70\\ 1\\ 40\\ 7\\ 35\\ 1\\ t^2 = 2.60\\ \mathbf{Pgy} \\ 5\end{array}$	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 98 98 11 11 10 12 13 16 00 467 70 73 5868 5855 5951, $p < 0.01$ 54 61	Proportion 0.797 0.769 0.909 0.636 0.999 0.500 0.500 0.63 0.861 0.881 0.881 0.881 0.882 0.885 0.	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.989 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.141, 0.882 \\ 0.715, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.636, 0.884 \\ 0.516, 0.979 \\ 0.336, 0.884 \\ 0.516, 0.979 \\ 0.621, 0.887 \\ 0.885, 0.991 \\ 0.780, 0.799 \\ 0.780, 0.955 \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Xiong 2023 Xiong 2023 Random effects mode Heterogenetly: / ² = 98%, g = liquid-based cytol- Scurry 2000	$\frac{4}{2}$ 3778 1 2 378 1 1 40 7 35 1 $\tau^2 = 2.60$ 999 5	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.769 0.999 0.636 0.999 0.500 0.634 0.897 0.685 0.857 0.85 0.857 0.	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.989 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.97, 1.000 \\ 0.97, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.668, 0.884 \\ 0.664, 0.979 \\ 0.546, 0.979 \\ 0.821, 0.887 \\ 0.885, 0.9911 \\ 0.720, 0.799 \\ 0.720, 0.955 \\ 0.778, 0.953 \\ 0.544, 0.963 \\ 0.544, 0.939 \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects mode Heterogeneity: / ² = 98%, g = liquid-based cytol Scurry 2000	378 378 1 6 70 1 40 7 35 4 40 7 7 2.60 999 5 1 1	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 98 98 11 11 10 12 13 16 00 467 70 73 5868 5855 5951, $p < 0.01$ 54 61	Proportion 0.797 0.769 0.909 0.636 0.999 0.500 0.500 0.63 0.861 0.881 0.881 0.881 0.882 0.885 0.	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.983 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.917, 1.000 \\ 0.9715, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.636, 0.884 \\ 0.516, 0.979 \\ 0.821, 0.887 \\ 0.544, 0.960 \\ 0.544, 0.960 \\ 0.780, 0.955 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.574, 0.887 \\ 0.478, 0.887 \\ 0.488, 0.487 \\ 0.488, 0.488 \\ 0$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Ucak 2021 Maurya 2023 Random effects mode Heterogeneity <i>I²</i> = 99%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008	378 378 1 6 70 1 40 7 35 4 40 7 7 2.60 5 999 5 1	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.797 0.799 0.030 0.999 0.500 0.500 0.694 0.897 0.694 0.881 0.832 0.881 0.832 0.852 0.959 0.761 0.897 0.761 0.897 0.714 0.923 0.998 0.714 0.923 0.998 0.714 0.923 0.998 0.99 0.99	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.983 \\ 0.398, 0.891 \\ 0.997, 1.000 \\ 0.118, 0.882 \\ 0.715, 1.000 \\ 0.664, 1.000 \\ 0.836, 0.884 \\ 0.516, 0.979 \\ 0.836, 0.884 \\ 0.516, 0.979 \\ 0.780, 0.951 \\ 0.836, 0.991 \\ 0.780, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.544, 0.939 \\ 0.578, 0.887 \\ 0.544, 0.939 \\ 0.578, 0.887 \\ 0.546, 0.993 \\ 0.478, 0.887 \\ 0.478, 0.887 \\ 0.478, 0.897 \\ 0.478, 0.953 \\ 0.996, 0.999 \\ 0.996, 0.999 \\ 0.996, 0.991 \\ 0.956, 0.991 \\ 0.$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: I ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008	$\begin{array}{c} 2 \\ 1 \\ 2 \\ 378 \\ 1 \\ 6 \\ 707 \\ 1 \\ 1 \\ 4 \\ 6 \\ 7 \\ 7 \\ 2 \\ 2 \\ 2 \\ 6 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 378 \end{array}$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.769 0.999 0.636 0.999 0.500 0.63 0.897 0.681 0.881 0.831 0.831 0.831 0.831 0.832 0.832 0.832 0.939 0.500 0.999 0.500 0.999 0.500 0.999 0.500 0.999 0.500 0.999 0.500 0.999 0.500 0.999 0.500 0.999 0.500 0.991 0.	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.989 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.971, 1.000 \\ 0.971, 1.000 \\ 0.971, 1.000 \\ 0.664, 1.000 \\ 0.684, 1.000 \\ 0.636, 0.884 \\ 0.516, 0.979 \\ 0.544, 0.960 \\ 0.821, 0.887 \\ 0.855, 0.991 \\ 0.780, 0.799 \\ 0.778, 0.955 \\ 0.778, 0.953 \\ 0.544, 0.939 \\ 0.478, 0.887 \\ 0.478, 0.887 \\ 0.4640, 0.998 \\ 0.996, 0.999 \\ 0.996, 0.999 \\ 0.968, 0.932 \\ 0.968, 0.932 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.982 \\ 0.998 \\ 0.996 \\ 0.998 \\ 0.996 \\ 0.998 \\ 0.996 \\ 0.998 \\ 0.9$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Xiong 2023 Xiong 2023 Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010	$\begin{array}{c} 2 \\ 1 \\ 2 \\ 376 \\ 1 \\ 1 \\ 6 \\ 7 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.796 0.799 0.500 0.699 0.500 0.694 0.694 0.861 0.801 0.801 0.802 0	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.989 \\ 0.308, 0.8911 \\ 0.997, 1.000 \\ 0.97, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.636, 0.884 \\ 0.666, 0.979 \\ 0.644, 0.960 \\ 0.836, 0.991 \\ 0.720, 0.799 \\ 0.720, 0.799 \\ 0.780, 0.955 \\ \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: J ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011	2 1 2 378 1 1 6 7 7 7 7 7 7 7 7 7 1 1 1 1 2 2 9 0 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.769 0.999 0.500 0.500 0.633 0.687 0.885 0.885 0.887 0	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.983 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.141, 0.882 \\ 0.715, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.636, 0.884 \\ 0.516, 0.979 \\ 0.544, 0.960 \\ 0.821, 0.887 \\ 0.780, 0.955 \\ \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Riong 2023 Random effects model Heterogeneity: 1 ² = 98%, g = liquid-based cytols Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Luu 2010 Koo 2011 Kim 2011	2 1 2 376 7 7 7 7 7 7 7 8 5 1 1 1 4 4 7 7 7 7 7 7 7 8 9 9 9 9 9 9 9 9 9 9 9 9	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.769 0.999 0.638 0.999 0.500 0.001 0	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.989 \\ 0.308, 0.891 \\ 0.907, 1.000 \\ 0.971, 1.000 \\ 0.971, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.630, 0.884 \\ 0.830, 0.884 \\ 0.836, 0.979 \\ 0.516, 0.979 \\ 0.544, 0.960 \\ 0.821, 0.887 \\ 0.780, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.867 \\ 0.640, 0.998 \\ 0.968, 0.932 \\ 0.787, 0.867 \\ 0.595, 0.983 \\ 0.565, 0.983 \\ 0.565, 0.983 \\ 0.565, 0.983 \\ 0.565, 0.983 \\ 0.565, 0.983 \\ 0.565, 0.983 \\ 0.565, 0.983 \\ 0.565, 0.983 \\ 0.562, 0.000 \\ 0.$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kurnar 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity. I ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kurnari 2020	2 1 2 37E 700 70 70 70 70 70 70 70 70 7	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.769 0.999 0.500 0.0000 0.000 0.000 0.00000 0.0000 0.0000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000000	
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kurani 2020 Rufai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity. 7 ² = 98%, g = ilquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kurnari 2020 Zhao 2020	2 1 2 378 378 7 7 7 38 7 7 38 1 1 1 1 1 1 1 1 1 1 1 1 1	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.983 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.1715, 1.000 \\ 0.664, 1.000 \\ 0.543, 0.783 \\ 0.544, 0.960 \\ 0.824, 0.884 \\ 0.516, 0.979 \\ 0.780, 0.799 \\ 0.780, 0.799 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.778, 0.955 \\ 0.787, 0.955 \\ 0.787, 0.955 \\ 0.787, 0.955 \\ 0.990, 0.955 \\ 0.9$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: / ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Kioo 2011 Kim 2011 Nagarajan 2015 Kuman 2020 Zhao 2020	2 378 $\frac{1}{2}$ 378 $\frac{1}{2}$ 378 $\frac{1}{1}$ 	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.769 0.909 0.636 0.999 0.500 0.607 0.681 0.881 0.881 0.881 0.881 0.881 0.882 0.882 0.687 0.959 0.500 0.687 0.897 0.959 0.500 0.687 0.89 0.998 0.	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.983 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.914, 1.000 \\ 0.975, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.636, 0.884 \\ 0.516, 0.979 \\ 0.544, 0.960 \\ 0.821, 0.887 \\ 0.885, 0.991 \\ 0.780, 0.799 \\ 0.780, 0.955 \\ \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: / ² = 98%, g = liquid-based cytols Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Jung 2008 Jung 2008 Jung 2011 Koo 2011 Kim 2011 Nagarajan 2015 Kumari 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2021	$\begin{array}{c} 2\\ 1\\ 2\\ 376\\ 1\\ 6\\ 77\\ 70\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\$	47 59 10 13 20 22 7 11 3 6 11 11 9 9 98 98 118 14 10 12 13 16 00 467 70 73 57 469 51 19 55 19 55 12 34 3792 2 4 12 364 13 15 10 10 26 31 10 10 17 39 100 17 24 418	Proportion 0.797 0.797 0.799 0.500 0.694 0.694 0.694 0.694 0.684 0.881 0.881 0.882 0.882 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.761 0.897 0.508 0.508 0.508 0.508 0.508 0.508 0.558 0.558 0.558 0.558 0.558 0.558 0.658 0.558 0.658 0.558 0.658 0.558 0.658	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.989 \\ 0.308, 0.891 \\ 0.907, 1.000 \\ 0.971, 1.000 \\ 0.971, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.683, 0.783 \\ 0.836, 0.884 \\ 0.516, 0.979 \\ 0.544, 0.960 \\ 0.821, 0.887 \\ 0.855, 0.991 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.787, 0.867 \\ 0.640, 0.998 \\ 0.966, 0.999 \\ 0.968, 0.932 \\ 0.787, 0.867 \\ 0.595, 0.963 \\ 0.682, 1.000 \\ 0.683, 0.945 \\ 0.329, 0.816 \\ 0.372, 0.699 \\ 0.940, 0.959 \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: <i>I²</i> = 98%, g = liquid-based cytol: Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kumai 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020	2 376 6 70 1 1 1 1 1 1 3 3 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion	$\begin{bmatrix} 0.\ 672,\ 0.\ 890 \\ 0.\ 462,\ 0.\ 950 \\ 0.\ 708,\ 0.\ 983 \\ 0.\ 997,\ 1.\ 000 \\ 0.\ 918,\ 0.\ 808,\ 0.\ 911 \\ 0.\ 971,\ 1.\ 000 \\ 0.\ 644,\ 1.\ 000 \\ 0.\ 648,\ 1.\ 000 \\ 0.\ 648,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 544,\ 0.\ 930 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 778,\ 0.\ 953 \\ 0.\ 787,\ 0.\ 953 \\ 0.\ 787,\ 0.\ 953 \\ 0.\ 952 \\ 0.\ 952 \\ 0.\ 952 \\ 0.\ 952 \\ 0.\ 953 \\ 0.\ 952 \\ 0.\ 953 \\ 0.\ 952 \\ 0.\ 953 \\ 0.\ 953 \\ 0.\ 952 \\ 0.\ 953 \ 0.\ 953 \\ 0.\ 953 \ 0.$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumari 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: / ² = 98%, g = liquid-based cytols Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Jung 2008 Jung 2008 Jung 2011 Koo 2011 Kim 2011 Nagarajan 2015 Kumari 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2021	2 376 377 1 2 377 1 1 4 4 4 4 4 4 4 5 5 1 1 1 1 1 1 1 2 2 5 5 5 5 5 5 5 5 5	47 59 10 13 20 22 7 11 3 6 11 11 9 9 98 98 118 14 10 12 13 16 00 467 70 73 57 469 51 19 55 19 55 12 34 3792 2 4 12 364 13 15 10 10 26 31 10 10 17 39 100 17 24 418	Proportion	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.989 \\ 0.308, 0.891 \\ 0.907, 1.000 \\ 0.971, 1.000 \\ 0.971, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.683, 0.783 \\ 0.836, 0.884 \\ 0.516, 0.979 \\ 0.544, 0.960 \\ 0.821, 0.887 \\ 0.855, 0.991 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.787, 0.867 \\ 0.640, 0.998 \\ 0.966, 0.999 \\ 0.968, 0.932 \\ 0.787, 0.867 \\ 0.595, 0.963 \\ 0.682, 1.000 \\ 0.683, 0.945 \\ 0.329, 0.816 \\ 0.372, 0.699 \\ 0.940, 0.959 \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity. I ² = 98%, g = liquid-based cytols Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Luu 2010 Kim 2011 Nagarajan 2015 Kumai 2020 Zhao 2020 Ucak 2021 Maurya 2023	4 1 2 376 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion	
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogenety: / ² = 98%, g = liquid-based cytols Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kumai 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Xiong 2023 Xiong 2023 Random effects model Heterogenetity: / ² = 96%,	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion	
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: J ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2017 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kuman 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Xiong 2023 Xiong 2024 Xiong 2025 Xiong 2025 Xiong 2026 Xiong 2027 Xiong 2027 Xiong 2028 Xiong 2028 Xi	2 377 1 2 377 7 7 7 7 7 7 7 7 7 1 1 4 0 3 7 7 7 7 7 7 2 2 6 3 0 0 3 7 7 7 7 7 7 7 7 7 7 7 2 2.60 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	47 59 10 13 20 22 27 11 34 3788 3 6 11 11 9 9 98 98 1814 11 10 12 13 16 00 467 70 73 7 469 5868 561, $p < 0.01$ 54 61 15 21 15 19 15 24 12 384 13 15 10 10 66 31 10 17 21 39 10 17 22 448 36 75 110 17 12 38 16 5010 00 43, $p < 0.01$	Proportion 0 797 0 769 0 909 0 636 0 999 0 500 1 000 0 684 0 881 0 881 0 883 0 883 0 883 0 883 0 885 0 769 0 500 1 000 0 684 0 885 0 789 0 500 0 887 0 959 0 500 0 887 0 959 0 500 0 887 0 885 0 789 0 500 0 887 0 959 0 959 0 0687 0 959 0 050 0 781 0 885 0 789 0 959 0 050 0 781 0 885 0 789 0 959 0 050 0 781 0 885 0 789 0 959 0 771 0 959 0 958 0 959 0 959 0 959 0 958 0 959 0 958 0 959 0 958 0 958 0 958 0 957 0 9	$\begin{bmatrix} 0.672, 0.890 \\ 0.462, 0.950 \\ 0.708, 0.983 \\ 0.308, 0.891 \\ 0.997, 1.000 \\ 0.971, 1.000 \\ 0.971, 1.000 \\ 0.971, 1.000 \\ 0.664, 1.000 \\ 0.664, 1.000 \\ 0.6821, 0.884 \\ 0.516, 0.979 \\ 0.821, 0.887 \\ 0.821, 0.887 \\ 0.821, 0.887 \\ 0.821, 0.887 \\ 0.821, 0.887 \\ 0.821, 0.887 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.778, 0.953 \\ 0.622, 0.999 \\ 0.668, 0.932 \\ 0.996, 0.999 \\ 0.668, 0.932 \\ 0.996, 0.999 \\ 0.668, 0.932 \\ 0.996, 0.999 \\ 0.668, 0.932 \\ 0.720, 0.993 \\ 0.663, 0.945 \\ 0.372, 0.699 \\ 0.372, 0.699 \\ 0.372, 0.699 \\ 0.374, 0.862 \\ 0.910, 0.953 \\ 0.817, 0.962 \\ 0.817, 0.962 \\ 0.220, 0.394 \\ 0.712, 0.930 \end{bmatrix}$
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufal 2020 Ucak 2021 Maurya 2023 Random effects mode Heterogenety: I ² = 98%, g = liquid-based cytols Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kumani 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Xiong 2023 Random effects mode Heterogenetty: I ² = 96%, g = liquid-based cytols Luu 2010	$\begin{array}{c} 2\\ 1\\ 2\\ 376\\ 1\\ 6\\ 7\\ 7\\ 1\\ 4\\ 4\\ 4\\ 7\\ 7\\ 7\\ 2\\ 2\\ 6\\ 3\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Proportion 0.797 0.799 0.500 0.999 0.500 0.684 0.885 0.885 0.789 0.684 0.885 0.897 0.761 0.897 0.694 0.885 0.897 0.789 0.789 0.789 0.789 0.789 0.789 0.789 0.789 0.789 0.789 0.789 0.885 0.885 0.830 0.830 0.830 0.830 0.830 0.830 0.830 0.830 0.830 0.830 0.830 0.858 0.830 0.830 0.858 0.830 0.830 0.830 0.858 0.830 0.830 0.830 0.858 0.830 0.830 0.858 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.538 0.634 0.852 0.538 0.53	
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: J ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2017 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kuman 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Xiong 2023 Xiong 2024 Xiong 2025 Xiong 2025 Xiong 2026 Xiong 2027 Xiong 2027 Xiong 2028 Xiong 2028 Xi	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 77\\ 77\\ 77\\ 77\\ 77\\ 77\\ 77\\ 77\\ 77\\ $	47 59 10 13 20 22 27 11 3 6 11 11 9 9 98 98 13 16 10 12 13 16 10 12 13 16 10 12 13 16 10 12 13 16 10 457 52 13 15 19 15 21 12 13 15 24 10 10 2 4 10 10 10 15 24 18 50 116 50 10 10 15 51 16 50 10 50 35 50	Proportion 0 797 0 799 0 999 0 030 0 999 0 500 0 080 0 081 0 881 0 881 0 883 0 885 0 989 0 500 0 080 0 000 0 0000 0 0000 0 000 0 000 0 000 0 000 0 000 00	[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.997; 1.000] [0.97; 1.000] [0.97; 1.000] [0.664; 1.000] [0.664; 1.000] [0.664; 1.000] [0.644; 0.960] [0.544; 0.960] [0.544; 0.960] [0.720; 0.799] [0.780; 0.955] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.643; 0.945] [0.643; 0.945] [0.362; 0.903] [0.663; 0.945] [0.322; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.371; 0.952] [0.220; 0.394] [0.712; 0.930]
g = direct smear Scurry 2000 Aftiy 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Rufai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogenetly. <i>1²</i> = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2010 Koo 2011 Kim 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kumai 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Scurry <i>2</i> = 98%, g = liquid-based cytol Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kumai 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Scurry <i>2</i> = 98%, g = liquid-based cytol Luu 2010 Kong 2012 Random effects model Heterogenetly. <i>1²</i> = 96%, g = liquid-based cytol Luu 2010 Chang 2012 Rufal 2020 Ucak 2021	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 1\\ 1\\ 777\\ 777\\ 777\\ 777\\ 777\\ 777\\ $	47 59 10 13 20 22 27 11 34 3788 33 6 11 19 9 9 98 111 11 141 10 12 13 16 100 467 7 409 5868 551 15 19 15 19 15 19 15 19 15 19 15 19 15 12 13 15 10 10 26 31 10 15 21 39 10 15 24 418 38 75 516 116 5010 10 43 9<<01	Proportion 0.797 0.799 0.799 0.999 0.500 0.899 0.500 0.694 0.885 0.885 0.885 0.789 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.899 0.500 0.694 0.999 0.500 0.899 0.694 0.895 0.761 0.897 0.999 0.500 0.694 0.852 0.835 0.835 0.835 0.835 0.835 0.835 0.835 0.835 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.852 0.999 0.500 0.855 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.999 0.500 0.855 0.995 0.995 0.000 0.855 0.995 0.995 0.000 0.855 0.995 0.995 0.995 0.995 0.000 0.855 0.99	
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Rufail 2020 Ucak 2021 Maurya 2023 Random effects mode Heterogeneity: J ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Kioo 2011 Kim 2011 Nagarajan 2015 Kuman 2020 Zhao 2020 Zhao 2020 Zhao 2020 Random effects mode Heterogeneity: J ² = 96%, g = liquid-based cytol- Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kong 2023 Random effects mode Heterogeneity: J ² = 96%, g = liquid-based cytol- Luu 2010 Chang 2012 Random effects mode	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\$	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 988 98 11 11 10 12 13 16 10 467 70 73 7 469 52 13 15 19 15 21 13 16 54 61 15 21 24 372 22 4 366 31 10 10 535 116 5010 10 10 15 10 17 21 39 10 15 5010 10 5010 10 516 11 516 <td>Proportion 0.797 0.769 0.909 0.500 0.899 0.500 0.881 0.881 0.881 0.881 0.881 0.887 0.959 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.781 0.897 0.999 0.500 0.897 0.500 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.897 0.500 0.885 0.781 0.897 0.500 0.885 0.781 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.085 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.</td> <td>[0.672; 0.890] [0.462; 0.950] [0.708; 0.989] [0.308; 0.891] [0.997; 1.000] [0.664; 1.000] [0.664; 1.000] [0.632; 0.884] [0.516; 0.979] [0.544; 0.960] [0.821; 0.887] [0.821; 0.887] [0.825; 0.991] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.478; 0.955] [0.478; 0.955] [0.478; 0.955] [0.640; 0.998] [0.968; 0.932] [0.786; 0.932] [0.329; 0.816] [0.329; 0.816] [0.329; 0.816] [0.329; 0.816] [0.329; 0.816] [0.329; 0.831] [0.220; 0.394] [0.220; 0.394] [0.2712; 0.930]</td>	Proportion 0.797 0.769 0.909 0.500 0.899 0.500 0.881 0.881 0.881 0.881 0.881 0.887 0.959 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.781 0.897 0.999 0.500 0.897 0.500 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.897 0.500 0.885 0.781 0.897 0.500 0.885 0.781 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.085 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.	[0.672; 0.890] [0.462; 0.950] [0.708; 0.989] [0.308; 0.891] [0.997; 1.000] [0.664; 1.000] [0.664; 1.000] [0.632; 0.884] [0.516; 0.979] [0.544; 0.960] [0.821; 0.887] [0.821; 0.887] [0.825; 0.991] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.478; 0.955] [0.478; 0.955] [0.478; 0.955] [0.640; 0.998] [0.968; 0.932] [0.786; 0.932] [0.329; 0.816] [0.329; 0.816] [0.329; 0.816] [0.329; 0.816] [0.329; 0.816] [0.329; 0.831] [0.220; 0.394] [0.220; 0.394] [0.2712; 0.930]
g = direct smear Scurry 2000 Aftiy 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Rufai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogenetly. <i>1²</i> = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2010 Koo 2011 Kim 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kumai 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Scurry <i>2</i> = 98%, g = liquid-based cytol Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kumai 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Zhao 2020 Scurry <i>2</i> = 98%, g = liquid-based cytol Luu 2010 Kong 2012 Random effects model Heterogenetly. <i>1²</i> = 96%, g = liquid-based cytol Luu 2010 Chang 2012 Rufal 2020 Ucak 2021	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\$	47 59 10 13 20 22 7 11 34 3788 3 6 11 11 9 9 988 98 11 11 10 12 13 16 10 467 70 73 7 469 52 13 15 19 15 21 13 16 54 61 15 21 24 372 22 4 366 31 10 10 535 116 5010 10 10 15 10 17 21 39 10 15 5010 10 5010 10 516 11 516 <td>Proportion 0.797 0.769 0.909 0.500 0.899 0.500 0.881 0.881 0.881 0.881 0.881 0.887 0.959 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.781 0.897 0.999 0.500 0.897 0.500 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.897 0.500 0.885 0.781 0.897 0.500 0.885 0.781 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.085 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.</td> <td>[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.836; 0.884] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.544; 0.939] [0.778; 0.955] [0.544; 0.939] [0.544; 0.939] [0.544; 0.939] [0.643; 0.945] [0.663; 0.945] [0.663; 0.945] [0.372; 0.699] [0.817; 0.952] [0.910; 0.950] [0.817; 0.951] [0.771; 0.931]</td>	Proportion 0.797 0.769 0.909 0.500 0.899 0.500 0.881 0.881 0.881 0.881 0.881 0.887 0.959 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.687 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.789 0.500 0.897 0.500 0.885 0.789 0.500 0.897 0.781 0.897 0.999 0.500 0.897 0.500 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.500 0.897 0.500 0.885 0.781 0.897 0.897 0.500 0.885 0.781 0.897 0.500 0.885 0.781 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.085 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.	[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.836; 0.884] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.544; 0.939] [0.778; 0.955] [0.544; 0.939] [0.544; 0.939] [0.544; 0.939] [0.643; 0.945] [0.663; 0.945] [0.663; 0.945] [0.372; 0.699] [0.817; 0.952] [0.910; 0.950] [0.817; 0.951] [0.771; 0.931]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: <i>I</i> ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kuman 2020 Zhao 2020 Cavaliere smodel Heterogeneity: <i>I</i> ² = 96%, g = liquid-based cytol Luu 2010 Chang 2012 Random effects model Heterogeneity: <i>I</i> ² = 96%,	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 77\\ 77\\ 77\\ 75\\ 77\\ 75\\ 77\\ 75\\ 77\\ 75\\ 77\\ 75\\ 77\\ 75\\ 77\\ 75\\ 77\\ 75\\ 77\\ 75\\ 75$	47 59 10 13 20 22 7 11 34 3788 3 6 11 19 9 9 988 988 11 11 10 12 13 16 10 12 13 16 5868 5851 551 19 552 13 54 61 15 21 13 15 14 3792 2 4 12 364 31 15 10 17 11 39 10 15 11 39 10 15 11 39 15 11 985 5010 10 46 15 491 985 <td>Proportion 0.797 0.769 0.909 0.500 0.801 0.811 0.821 0.857 0.857 0.859 0.761 0.897 0.857 0.959 0.959 0.500 0.857 0.959 0.500 0.857 0.999 0.997 0.99</td> <td>[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.664; 1.000] [0.684; 0.963] [0.644; 0.960] [0.770; 0.965] [0.770; 0.955] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.955] [0.778; 0.953] [0.478; 0.887] [0.668; 0.932] [0.770; 0.963] [0.663; 0.945] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.693] [0.372; 0.930] [0.771; 0.930] [0.771; 0.951] [0.386; 0.677] [0.386; 0.671] [0.386; 0.671]</td>	Proportion 0.797 0.769 0.909 0.500 0.801 0.811 0.821 0.857 0.857 0.859 0.761 0.897 0.857 0.959 0.959 0.500 0.857 0.959 0.500 0.857 0.999 0.997 0.99	[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.664; 1.000] [0.684; 0.963] [0.644; 0.960] [0.770; 0.965] [0.770; 0.955] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.955] [0.778; 0.953] [0.478; 0.887] [0.668; 0.932] [0.770; 0.963] [0.663; 0.945] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.693] [0.372; 0.930] [0.771; 0.930] [0.771; 0.951] [0.386; 0.677] [0.386; 0.671] [0.386; 0.671]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity / ² = 98%, g = liquid-based cytol Scurry 2000 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kuman 2020 Zhao	$\begin{array}{c} 4\\ 2\\ 376\\ 1\\ 1\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\ 7\\$	47 59 10 13 20 22 27 11 34 3788 33 6 11 19 9 9 988 98 11 11 13 16 100 12 13 16 101 21 133 16 100 467 70 73 57 469 5868 51 51 19 15 19 122 13 13 15 100 17 12 364 310 10 22 4 2364 3792 361 5010 363 5010 363 5010 363 5010 364 5010 37 491 <t< td=""><td>Proportion 0.797 0.799 0.500 0.809 0.000 0.801 0.80</td><td>[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.836; 0.884] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.544; 0.939] [0.778; 0.955] [0.544; 0.939] [0.544; 0.939] [0.544; 0.939] [0.643; 0.945] [0.663; 0.945] [0.663; 0.945] [0.372; 0.699] [0.817; 0.952] [0.910; 0.950] [0.817; 0.951] [0.771; 0.931]</td></t<>	Proportion 0.797 0.799 0.500 0.809 0.000 0.801 0.80	[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.836; 0.884] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.544; 0.960] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.778; 0.955] [0.544; 0.939] [0.778; 0.955] [0.544; 0.939] [0.544; 0.939] [0.544; 0.939] [0.643; 0.945] [0.663; 0.945] [0.663; 0.945] [0.372; 0.699] [0.817; 0.952] [0.910; 0.950] [0.817; 0.951] [0.771; 0.931]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kuman 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: <i>I</i> ² = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Koo 2011 Kim 2011 Nagarajan 2015 Kuman 2020 Zhao 2020 Cavaliere smodel Heterogeneity: <i>I</i> ² = 96%, g = liquid-based cytol Luu 2010 Chang 2012 Random effects model Heterogeneity: <i>I</i> ² = 96%,	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 777\\ 777\\ 777\\ 777\\ 777\\ 777\\ 777$	47 59 10 13 20 22 27 11 34 3788 33 6 11 19 9 9 98 98 10 12 13 16 10 467 70 73 5868 551, $p < 0.01$ 54 61 15 21 13 16 52 2 4 3782 2 4 12 13 15 21 13 15 14 3792 2 4 13 16 5010 10 13 15 11 39 38 75 5 116 5 491 5 491 5 495 5	Proportion 0.797 0.799 0.500 0.809 0.000 0.801 0.80	[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.664; 1.000] [0.684; 0.963] [0.644; 0.960] [0.770; 0.965] [0.770; 0.955] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.955] [0.778; 0.953] [0.478; 0.887] [0.668; 0.932] [0.770; 0.963] [0.663; 0.945] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.693] [0.372; 0.930] [0.771; 0.930] [0.771; 0.951] [0.386; 0.677] [0.386; 0.671] [0.386; 0.671]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: <i>I²</i> = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cochand?Priollet 2003 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2012 Zhao 2020 Zhao	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 777\\ 777\\ 777\\ 777\\ 777\\ 777\\ 777$	47 59 10 13 20 22 27 11 34 3788 33 6 11 19 9 9 98 98 10 12 13 16 10 467 70 73 5868 551, $p < 0.01$ 54 61 15 21 13 16 52 2 4 3782 2 4 12 13 15 21 13 15 14 3792 2 4 13 16 5010 10 13 15 11 39 38 75 5 116 5 491 5 491 5 495 5	Proportion 0 797 0 799 0 999 0 500 0 809 0 009 0 009 0 009 0 000 0 000 0 009 0 000 0 0000 0 000 0 0000 0 000 0 000 0 000 0 000 0 000 0 000 0 000 0	[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.664; 1.000] [0.684; 0.963] [0.644; 0.960] [0.770; 0.965] [0.770; 0.955] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.955] [0.778; 0.953] [0.478; 0.887] [0.668; 0.932] [0.770; 0.963] [0.663; 0.945] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.693] [0.372; 0.930] [0.771; 0.930] [0.771; 0.951] [0.386; 0.677] [0.386; 0.671] [0.386; 0.671]
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumai 2020 Ucak 2021 Maurya 2023 Random effects model Heterogeneity: <i>I²</i> = 98%, g = liquid-based cytol Scurry 2000 Afify 2001 Cochand?Priollet 2003 Kim 2007 Cochand?Priollet 2003 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2011 Kim 2012 Zhao 2020 Zhao	$\begin{array}{c} 4\\ 1\\ 2\\ 376\\ 777\\ 777\\ 777\\ 777\\ 777\\ 777\\ 777$	47 59 10 13 20 22 27 11 34 3788 33 6 11 19 9 9 98 98 10 12 13 16 10 467 70 73 5868 551, $p < 0.01$ 54 61 15 21 13 16 52 2 4 3782 2 4 12 13 15 21 13 16 63 11 10 17 11 39 11 39 15 11 16 5010 17 54 1863 116 5010 95 5401 985 5401 985	Proportion 0 797 0 799 0 999 0 500 0 809 0 0 809 0 0 809 0 0 809 0 0 800 0 0 804 0 887 0 999 0 500 0 887 0 999 0 500 0 887 0 887 0 999 0 500 0 887 0 887 0 999 0 500 0 887 0 999 0 500 0 887 0 999 0 500 0 887 0 999 0 500 0 887 0 887 0 999 0 500 0 999 0 500 0 999 0 500 0 887 0 999 0 500 0 997 0 998 0 500 0 997 0 998 0 500 0 998 0 998 0 500 0 998 0 997 0 998 0 998 0 998 0 998 0 998 0 997 0 998 0 997 0 998 0 997 0 998 0 998 0 997 0 997 0 997 0 997 0 998 0 997 0 997 0 997 0 997 0 997 0 997 0 998 0 997 0	[0.672; 0.890] [0.462; 0.950] [0.708; 0.983] [0.308; 0.891] [0.997; 1.000] [0.118; 0.882] [0.715; 1.000] [0.664; 1.000] [0.664; 1.000] [0.684; 0.963] [0.644; 0.960] [0.770; 0.965] [0.770; 0.955] [0.778; 0.953] [0.778; 0.953] [0.778; 0.953] [0.778; 0.955] [0.778; 0.953] [0.478; 0.887] [0.668; 0.932] [0.770; 0.963] [0.663; 0.945] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.699] [0.384; 0.882] [0.372; 0.693] [0.372; 0.930] [0.771; 0.930] [0.771; 0.951] [0.386; 0.677] [0.386; 0.671] [0.386; 0.671]

9 of 18

Figure 3. Cont.

	Experimental Events Total	Control Events Total	Odds Ratio	OR	95%-Cl Weight
g = direct smear Scury 2000 Afity 2001 Cochard/Phollet 2003 Kim 2007 Cavaliere 2008 Jung 2006 Koo 2011 Kim 2011 Chang 2012 Nagarajan 2015 Kumar 2020 Rufail 2020 Ucak 2021 Mauya 2023 Xiong 2023 Xiong 2023 Random effects model Heterogenety. I ² = 83%, I ²		12 59 3 13 2 22 4 11 4 3768 3 66 0 11 0 9 30 98 113 814 2 12 3 73 112 469 5858		15.000 23.000 [11.667 658.087 [23 28.000 [437.000 [39.267 [6.681 21.116 [79.800 [50.143 [12.386 110.833 [²] 10.769	2 509; 16.082; 3.5% 12 782; 80.867; 2.8%, 4 407; 117.644; 2.9%, 0.885; 1875;733; 3.4%, 2 170; 361:215; 2.1%, 2 170; 361:215; 2.1%, 2 006; 786:791; 1.8%, 3 206; 716:715; 2.87%, 3 206; 716:73; 3.8%, 2 2241; 123:842; 100; 2 2816; 538:346; 2.9%, 7 0.49; 16.452; 3.8%, 13.47; 41.579; 41.9%,
g = Ilquid-based cytolog Scury 2000 Afity 2001 Cochard/Phollet 2003 Kim 2007 Cavaliere 2008 Jung 2008 Luu 2010 Kon 2011 Nagarajan 2015 Kumari 2020 Zhao 2020 Zhao 2020 Ucak 2021 Mauya 2023 Xiong 2023 Random effects model Heterogenety. I ² = 90%, c ²	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	7 61 4 19 6 21 1 13 8 3792 2 4 62 364 2 15 0 10 5 31 7 17 18 39 5 15 26 418 7 75 81 116 5010		7,500 6,000 [1 233,072 [1 14,500 [1 59,400 [1 54,600 [266,135 [1 204,273 [1 33,870 [24,286] 0,308	4 195, 35.565 3.4% 1 469, 38.280 2.9% 1 1407, 19.25 3.3% 1 1807, 19.25 3.3% 1 583, 3593.007 1.9% 1 0406, 52.1905 3.6% 1 0406, 52.1905 3.6% 1 1047, 72.727 3.8% 2 436; 1 448.711 1.7% 2 540, 987.097 1.8% 9.605, 310.369 2.8% 0.566, 27.097 1.8% 9.605, 310.369 2.8% 0.566, 27.097 1.8% 7.137, 82.763 8.5% (0.201, 0.473) 3.8% (7.137, 89.475) 43.3%
g = liquid-based cytolog Luu 2010 Chang 2012 Rufail 2020 Ucak 2021 Random effects model Heterogeneity: / ² = 94%, c ²	132 174 148 183 17 57 299 388 802	57 357 46 91 6 46 46 491 985	∎ # ®	4.137 2.833 32.500 [10.568; 25.892] 3.8% [2.382; 7.183] 3.7% [1.013; 7.926] 3.4% 22.117; 47.758] 3.8% (3.298; 27.114] 14.7%
Random effects model Heterogeneity: $I^2 = 93\%$, τ^2 Residual heterogeneity: I^2	3998 = 1.9717, p < 0.1 = 94%, p < 0.01	11863	0.001 0.1 1 10 1000	-	12.326; 36.461] 100.0%
			(d)		
Study	Events	Total	:	Prop	ortion 95%-Cl
g = direct smear Scurry 2000 Afify 2001 Cochand?Priollet 200 Malle 2006 Kim 2007 Cavaliere 2008 Jung 2008 Saleh 2008 Saleh 2008 Koo 2011 Chang 2012 Nagarajan 2015 Gupta 2018 Kumari 2020 Rufail 2020 Mahajan 2021 Alam 2022 Sayer 2022 Maurya 2023 Random effects mo Heterogeneity. 1 ² = 989	$\begin{array}{c} 8\\ 36\\ 1446\\ 12\\ 45\\ 322\\ 458\\ 516\\ 22\\ 5\\ 5\\ 10\\ 199\\ 63\\ 3\\ \text{del}\\ 6, \tau^2 = 0.859 \end{array}$	109 46 285 172 3875 193 1767 5169 60 73 200 1311 266 250 13195 30, p < 0.01			0.367 [0.277; 0.465] 0.196 [0.094; 0.339] 0.083 [0.041; 0.148] 0.028 [0.012; 0.055] 0.209 [0.151; 0.278] 0.365 [0.350; 0.381] 0.062 [0.033; 0.106] 0.357 [0.274; 0.447] 0.166 [0.116; 0.226] 0.259 [0.239; 0.280] 0.033 [0.004; 0.115] 0.033 [0.004; 0.115] 0.033 [0.028; 0.184] 0.035 [0.014; 0.071] 0.055 [0.014; 0.071] 0.052 [0.028; 0.087] 0.128 [0.087; 0.185]
g = liquid-based cyt Scury 2000 Afify 2001 Cochand?Priollet 200 Malle 2006 Kim 2007 Cavaliere 2008 Saleh 2008 Saleh 2008 Luu 2010 Koo 2011 Nagarajan 2015 Kumari 2020 Mahajan 2021 Alam 2022 Sayer 2022 Maurya 2023 Random effects mod Heterogeneity: 1 ² = 979 g = liquid-based cyt Luu 2010 Chang 2012 Rufail 2020	$\begin{array}{c} 31\\ 26\\ 32\\ 7\\ 16\\ 1252\\ 10\\ 40\\ 173\\ 96\\ 52\\ 14\\ 39\\ 6\\ 52\\ 24\\ 9\\ 39\\ del\\ 6, \tau^2=0.614\\ 174\\ 318\\ 65\end{array}$	3875 193 126 2102 193 306 100 200 131 359 250 8486 8, p < 0.01 direct sme 2000		-	0.344 [0.247; 0.452] 0.274 [0.187; 0.375] 0.225 [0.154; 0.310] 0.040 [0.016; 0.081] 0.093 [0.054; 0.147] 0.323 [0.308; 0.338] 0.052 [0.025; 0.093] 0.317 [0.237; 0.406] 0.082 [0.071; 0.095] 0.497 [0.425; 0.570] 0.170 [0.130; 0.217] 0.140 [0.129; 0.224] 0.180 [0.129; 0.243] 0.186 [0.103; 0.176] 0.156 [0.113; 0.237] 0.087 [0.075; 0.100] 0.127 [0.100] 0.128 [0.149] 0.141 [0.099; 0.136]
Heterogeneity: $I^2 = 829$ Random effects mo Heterogeneity: $I^2 = 989$ Residual heterogeneity	6, $\tau^2 = 0.032$ del 6, $\tau^2 = 0.709$	9, p < 0.01 26715 6, p = 0	0.1 0.2 0.3 0.4	□ 0.5	0.145 [0.113; 0.183]



Figure 3. Forest plots of sensitivities (**a**), specificities (**b**), negative predictive values (**c**), diagnostic odd ratios (**d**), and rate of inadequate specimen (**e**).

For all LBP methods combined, the DOR was 25.3587 (95% CI [7.1871; 89.4747]; $I^2 = 95.9\%$) (Figure 3). The AUC was 0.865 (Figure 4). Sensitivity, specificity, and negative predictive value were 0.8190 (95% CI [0.7459; 0.8746]; $I^2 = 83.8\%$), 0.8833 (95% CI [0.7348; 0.9539]; $I^2 = 97.8\%$), and 0.8515 (95% CI [0.7124; 0.9300]; $I^2 = 95.6\%$), respectively. The RIS was 0.1729 (95% CI [0.1231; 0.2375]; $I^2 = 97.0\%$).

When combining CS with LBP, the DOR was 9.4557 (95% CI [3.2976; 27.1139]; $I^2 = 93.6\%$) (Figure 3). The AUC was 0.813 (Figure 4). Sensitivity, specificity, and negative predictive value were 0.7809 (95% CI [0.6976; 0.8463]; $I^2 = 79.6\%$), 0.7267 (95% CI [0.5370; 0.8591]; $I^2 = 95.8\%$), and 0.8111 (95% CI [0.6388; 0.9125]; $I^2 = 95.2\%$), respectively. The RIS was 0.1109 (95% CI [0.0901; 0.1357]; $I^2 = 82.1\%$).

0.1 Δ Δ Δ Δ Δ Δ Δ Δ $\Delta \Delta$ 80 Δ Δ Δ \wedge Δ Δ \wedge Δ 0.6 Sensitivity 4 Δ 0.2 SROC 0.0 95% Cl region 0.0 0.2 0.4 0.6 0.8 1.0 False Positive Rate (a) SROC curve (bivariate model) 0 Δ Δ Δ Δ Δ Δ 80 Δ 0.6 Sensitivity Λ 0 4 0.2 SROC 0.0 95% CI region 0.0 0.2 0.4 0.6 0.8 1.0 False Positive Rate (b)

SROC curve (bivariate model)

Figure 4. Cont.




Figure 4. The summary receiver operating characteristic curve of (**a**) all included studies, (**b**) conventional smear, (**c**) liquid-based preparations, and (**d**) combination of conventional smear with liquid-based preparations. Thick curve line (summary receiver operating characteristic curve), thin circular line (95% confident region), and small circle (summary estimate).

While there were no statistically significant differences in diagnostic accuracy and RIS among CS, LBP, and their combination, CS plus LBP appeared to have a relatively lower diagnostic accuracy compared to CS and LBP individually. Conversely, the combination of CS with LBP tended to reduce the RIS (Supplementary Table S2).

3.3. Subgroup Analysis of Diagnostic Accuracy According to the Methods of LBP

Several LBP kits were included in the enrolled comparative studies, including Thin-Prep, SurePath, CellPrepPlus, and an unspecified tool. Among these, ThinPrep and SurePath are the most commonly used. A subgroup analysis was conducted to determine which method is more accurate for diagnosing thyroid malignancies or suspicious lesions.

For ThinPrep, the DOR was 29.1494 (95% CI [4.9108; 173.0254]; $I^2 = 89.6\%$). The AUC was 0.791. Sensitivity, specificity, negative predictive value, and positive predictive value were 0.8182 (95% CI [0.7403; 0.8767]; $I^2 = 8.7\%$), 0.9080 (95% CI [0.7064; 0.9759]; $I^2 = 94.7\%$), 0.8988 (95% CI [0.5741; 0.9832]; $I^2 = 96.4\%$), and 0.7989 (95% CI [0.3465; 0.9675]; $I^2 = 96.7\%$), respectively.

For SurePath, the DOR was 19.7734 (95% CI [1.6023; 244.0203]; $I^2 = 93.5\%$). The AUC was 0.841. Sensitivity, specificity, negative predictive value, and positive predictive value were 0.8573 (95% CI [0.6806; 0.9442]; $I^2 = 86.4\%$), 0.8368 (95% CI [0.4211; 0.9731]; $I^2 = 94.6\%$), 0.7573 (95% CI [0.5036; 0.9057]; $I^2 = 87.4\%$), and 0.8966 (95% CI [0.6509; 0.9758]; $I^2 = 92.1\%$), respectively.

There were no statistically significant differences in diagnostic accuracy between CS, ThinPrep, and SurePath (Supplementary Table S3). However, when comparing the two kits (ThinPrep and SurePath), significant differences in the AUC (0.791 vs. 0.841; p = 0.019) were observed, suggesting that SurePath might be more accurate.

4. Discussion

FNAC of thyroid lesions is a classic, safe, and meaningful test, playing an important role in diagnosing thyroid lesions and guiding treatment [9]. However, the efficacy and superiority of CS and LBP for FNAC in diagnosing thyroid lesions remain contentious. We analyzed the diagnostic accuracy of CS and LBP by comparing DOR, sensitivity, specificity, and AUC.

Our findings revealed no significant difference in diagnostic accuracy between CS, LBP, and the combination of CS with LBP. The diagnostic accuracy of CS and LBP was similar, while the accuracy of combining CS with LBP was notably lower. Sensitivity, specificity, and negative predictive value were also lower when combining CS with LBP compared to CS and LBP individually, but the differences were not statistically significant. Previous studies have reported no significant difference in diagnostic accuracy between CS and LBP [10,30,40,50]. Sensitivity has varied, reported as 78.9–93.6% for CS and 65.9–93.9% for LBP [25,26,30].

In previous studies, combining CS with LBP has been shown to reduce unnecessary thyroidectomies. LBP serves as a useful adjunct diagnostic tool for CS to identify malignant or suspicious thyroid lesions [9,46]. The rate of non-diagnostic results decreased when CS was combined with LBP, although not significantly, compared to CS alone [51]. However, in our study, combining CS with LBP resulted in relatively low diagnostic accuracy. Rossi et al. noted that slide adequacy assessed via CS indicated an increase in the non-diagnostic rate when using CS and LBP together [52]. In LBP, cells are preserved in a solution, preventing the real-time determination of sample adequacy [23,31]. Nonetheless, LBP can result in a relatively lower non-diagnostic rate due to a clearer background and fewer drying artifacts, provided that CS is not employed for on-site adequacy evaluation [51]. If slide cellularity is insufficient, additional slides can be utilized [7,30]. The combination of CS and LBP enables efficient slide preparation without compromising slide adequacy [53,54].

Our subgroup analysis of LBP kits revealed no significant differences in diagnostic accuracy between CS, ThinPrep, and SurePath. While SurePath had a lower DOR, its AUC was significantly higher, and there were no significant differences in the DOR, sensitivity, specificity, negative predictive value, and positive predictive value. A previous study reported that SurePath or ThinPrep achieved similar or marginally improved sensitivity and specificity compared to CS [8]. However, most studies on SurePath have been conducted in Belgium or Korea, limiting their generalizability. Furthermore, other studies have reported high sensitivity and specificity for both CS and SurePath [55]. Further studies on different LBP kits and in various countries could enhance the generalizability of the results.

Regarding the RIS, previous studies have reported variability in LBP, ranging from 10% to 25% [24,38,56]. One study observed better sample adequacy in LBP compared

to CS [8], while another indicated a higher inadequacy rate for LBP than CS [31]. Our findings are similar to a previous study that found that combining CS with LBP resulted in a lower RIS compared to using either method alone [5], although this was not statistically significant. In LBP, the RIS may increase due to cell dilution in suspension media or loss of colloids during processing [9]. Repeated processing using LBP could mitigate this, enhancing sample adequacy and diagnostic accuracy [56]. The accumulation of clinical data and a learning curve are essential to improve the adequacy of LBP samples. As a newer technology compared to CS, LBP requires enhanced technical skills, such as syringe cleaning, to address issues such as low levels of cytoplasm in samples. In addition, the learning curve for cytopathologists, particularly in recognizing colloids and follicles, must be improved [10]. It is also important to consider the potential unclear effects of preservative solutions and artifacts that reduce inflammatory cells in LBP [10].

In previous studies, ease of interpretation has generally not correlated with the RIS. Only 3–5% of studies have evaluated LBP as being good for ease of interpretation compared to CS [9,38]. Moreover, studies that have assessed inadequate specimen rates have mainly focused on the SurePath or ThinPrep kits; more research is needed on other new LBP tests and technologies.

In our study, there were no significant differences between CS and LBP, and combining CS with LBP did not yield better results. Subgroup analyses also suggested that using CS or LBP alone might be preferable, with SurePath being the recommended choice when using LBP. However, the advantage of the combination could be considered in cases where specimen collection is challenging, as the RIS was lower, although not statistically significant.

Furthermore, cytomorphological differences between LBP and CS may vary in papillary, anaplastic, and medullary carcinoma. Papillary carcinoma can exhibit diverse cell arrangements [57,58]. Although CS and LBP do not allow for the detailed observation of tissue structure, understanding the clinical significance of morphological features is important [6]. Adding LBP can help distinguish between benign and malignant lesions due to better nuclear observation in a clear background [51]. Therefore, immunocytochemical and molecular studies should be concurrently considered for malignant or suspicious lesions as they can provide additional diagnostic assistance. If the FNAC results are uncertain, molecular testing for mutations such as BRAF and RAS can be useful [59]. Nuclei remain stable for up to 6 months in LBP preservative solution, potentially ensuring high reliability in mutation testing [7,60].

This study had several limitations. First, statistical heterogeneity was high, which is common in pathological studies [61], but the sampling methods and LBP techniques were not uniformly represented. The heterogeneity in the subgroup analyses for SurePath and ThinPrep might have stemmed from varied study designs and differences in LBP proficiency among examiners. The presence or absence of a cytopathologist and the use of different instruments and ultrasonography in the FNAC process also contributed to variability. In order to increase diagnostic accuracy, using the Bethesda Reporting System with ultrasonography, other appropriate diagnostic criteria could have been applied, such as Thyroid Imaging Reporting and Data System. Second, histologic follow-up was not included in the analysis, potentially limiting the evaluation, as most cases analyzed only initial diagnoses without considering final pathological diagnoses or modified FNAC diagnoses post-surgery. Further studies that incorporate histological follow-up are necessary. Third, the retrospective nature of several studies could have introduced bias, as non-diagnostic nodules were excluded after surgery. Cases suspected of follicular neoplasm or those without surgical intervention for non-diagnostic lesions may have been omitted. Fourth, CS, LBP, and their combination might not have been performed on the same thyroid lesion. Fifth, because the cytologic categories were different for each included study, it was difficult to evaluate benign and atypia lesions. Further studies evaluating malignancy risk for benign and atypia lesions in included studies with the same cytologic category are needed. Finally, most studies were from the United States, Europe, and Korea, possibly introducing bias due to limited racial diversity.

To supplement the accuracy and feasibility of CS and LBP, repeated processing is required, along with improving sample adequacy and diagnostic accuracy. The accumulation of clinical data and a learning curve are critical for improving the adequacy of LBP samples. LBP necessitates more advanced technical skills, and the learning curve for cytopathologists needs to be improved. Our subgroup analyses indicated that using CS or LBP alone may be preferable, with SurePath being the recommended option when using LBP. Although not statistically significant, the combination's benefit might be taken into account in situations where collecting specimens is difficult.

5. Conclusions

There were no significant differences in diagnostic accuracy and RIS among CS, LBP, and their combination. While combining CS and LBP resulted in lower diagnostic accuracy and a decreased RIS, CS and LBP demonstrated similar accuracy. There were no significant differences in diagnostic accuracy among CS, ThinPrep, and SurePath. However, significant differences in the AUC suggest that the SurePath kit might be more accurate. Therefore, when choosing FNAC methods, cost, feasibility, and accuracy should all be considered.

Supplementary Materials: The following supporting information can be downloaded at: https:// www.mdpi.com/article/10.3390/cancers16040751/s1, Table S1: Diagnostic subjects and excluded intermediate case of the included studies; Table S2: Comparative analysis of sensitivities, specificities, negative predictive values, diagnostic odd ratios, and rate of inadequate specimen; Table S3: Subgroup analysis of sensitivities, specificities, negative predictive values, diagnostic odd ratios, and rate of inadequate specimen.

Author Contributions: Conceptualization, Y.J.K. and S.H.H.; methodology, S.H.H. and G.S.; software, G.S.; validation, Y.J.K. and S.H.H.; formal analysis, S.H.H.; data curation, Y.J.K.; writing—original draft preparation, Y.J.K. and H.W.L.; writing—review and editing, Y.J.K., G.S., H.W.L. and S.H.H.; visualization, S.H.H.; supervision, S.H.H.; project administration, S.H.H.; All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2022R1F1A1066232). And this work was supported by the Soonchunhyang University Hospital Cheonan Research Fund. The sponsors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created as part of this systematic review.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- Tripathy, K.; Misra, A.; Ghosh, J.K. Efficacy of liquid-based cytology versus conventional smears in FNA samples. J. Cytol. 2015, 32, 17–20. [CrossRef] [PubMed]
- Dong, W.; Zhang, H.; Zhang, P.; Li, X.; He, L.; Wang, Z.; Liu, Y. The changing incidence of thyroid carcinoma in Shenyang, China before and after universal salt iodization. *Med. Sci. Monit.* 2013, *19*, 49–53. [CrossRef] [PubMed]
- La Vecchia, C.; Malvezzi, M.; Bosetti, C.; Garavello, W.; Bertuccio, P.; Levi, F.; Negri, E. Thyroid cancer mortality and incidence: A global overview. *Int. J. Cancer* 2015, 136, 2187–2195. [CrossRef]
- Rana, C.; Singh, K.R.; Ramakant, P.; Babu, S.; Mishra, A. Impact of cytological pitfalls in the Bethesda System of Reporting Thyroid Cytopathology, on surgical decision-making of patients with thyroid nodules: Can these pitfalls be avoided? *Cytopathology* 2021, 32, 192–204. [CrossRef] [PubMed]
- Feldkamp, J.; Führer, D.; Luster, M.; Musholt, T.J.; Spitzweg, C.; Schott, M. Fine Needle Aspiration in the Investigation of Thyroid Nodules. *Dtsch. Arztebl. Int.* 2016, 113, 353–359. [CrossRef]
- Xiong, X.J.; Xiao, M.M.; Zhang, Y.X.; Liu, D.G.; Jin, M.L.; Wang, J.; Xu, H.T.; Li, Q.C.; Wu, G.P. The Accurate Interpretation and Clinical Significance of Morphological Features of Fine Needle Aspiration Cells in Papillary Thyroid Carcinoma. *Anal. Cell. Pathol.* 2023, 2023, 9397755. [CrossRef]
- Fadda, G.; Rossi, E.D. Liquid-based cytology in fine-needle aspiration biopsies of the thyroid gland. *Acta Cytol.* 2011, 55, 389–400. [CrossRef]

- 8. Chong, Y.; Ji, S.J.; Kang, C.S.; Lee, E.J. Can liquid-based preparation substitute for conventional smear in thyroid fine-needle aspiration? A systematic review based on meta-analysis. *Endocr. Connect.* **2017**, *6*, 817–829. [CrossRef]
- 9. Maurya, M.K.; Yadav, R.; Kumar, M.; Singh, H.P.; Mishra, A.; Goel, M.M. A Comparative Analysis of Liquid-Based Cytology and Conventional Smears in Fine-Needle Aspirates of Thyroid Lesions. *Cureus* **2023**, *15*, e45353. [CrossRef]
- 10. Nagarajan, N.; Najafian, A.; Schneider, E.B.; Zeiger, M.A.; Olson, M.T. Conventional smears versus liquid-based preparations for thyroid fine-needle aspirates: A systematic review and meta-analysis. *J. Am. Soc. Cytopathol.* **2015**, *4*, 253–260. [CrossRef]
- 11. Scappaticcio, L.; Trimboli, P.; Iorio, S.; Maiorino, M.I.; Longo, M.; Croce, L.; Pignatelli, M.F.; Ferrandes, S.; Cozzolino, I.; Montella, M.; et al. Repeat thyroid FNAC: Inter-observer agreement among high- and low-volume centers in Naples metropolitan area and correlation with the EU-TIRADS. *Front. Endocrinol.* **2022**, *13*, 1001728. [CrossRef]
- 12. Rossi, E.D.; Morassi, F.; Santeusanio, G.; Zannoni, G.F.; Fadda, G. Thyroid fine needle aspiration cytology processed by ThinPrep: An additional slide decreased the number of inadequate results. *Cytopathology* **2010**, *21*, 97–102. [CrossRef]
- 13. Ryu, H.S.; Park, I.A.; Park, S.Y.; Jung, Y.Y.; Park, S.H.; Shin, H.C. A pilot study evaluating liquid-based fine needle aspiration cytology of breast lesions: A cytomorphological comparison of SurePath[®] liquid-based preparations and conventional smears. *Acta Cytol.* **2013**, *57*, 391–399. [CrossRef]
- Fadda, G.; Rossi, E.D.; Raffaelli, M.; Mulè, A.; Pontecorvi, A.; Miraglia, A.; Lombardi, C.P.; Vecchio, F.M. Fine-needle aspiration biopsy of thyroid lesions processed by thin-layer cytology: One-year institutional experience with histologic correlation. *Thyroid* 2006, 16, 975–981. [CrossRef]
- 15. Doyle, B.; O'Farrell, C.; Mahoney, E.; Turner, L.; Magee, D.; Gibbons, D. Liquid-based cytology improves productivity in cervical cytology screening. *Cytopathology* **2006**, *17*, 60–64. [CrossRef] [PubMed]
- 16. Dey, P.; Luthra, U.K.; George, J.; Zuhairy, F.; George, S.S.; Haji, B.I. Comparison of ThinPrep and conventional preparations on fine needle aspiration cytology material. *Acta Cytol.* **2000**, *44*, 46–50. [CrossRef] [PubMed]
- 17. Malle, D.; Valeri, R.M.; Pazaitou-Panajiotou, K.; Kiziridou, A.; Vainas, I.; Destouni, C. Use of a thin-layer technique in thyroid fine needle aspiration. *Acta Cytol.* 2006, *50*, 23–27. [CrossRef] [PubMed]
- Cibas, E.S.; Ali, S.Z. The 2017 Bethesda System for Reporting Thyroid Cytopathology. *Thyroid* 2017, 27, 1341–1346. [CrossRef] [PubMed]
- 19. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* 2009, 339, b2535. [CrossRef]
- Goossen, K.; Tenckhoff, S.; Probst, P.; Grummich, K.; Mihaljevic, A.L.; Büchler, M.W.; Diener, M.K. Optimal literature search for systematic reviews in surgery. *Langenbecks Arch. Surg.* 2018, 403, 119–129. [CrossRef] [PubMed]
- 21. Kang, Y.J.; Stybayeva, G.; Hwang, S.H. Comparative Effectiveness of Cryotherapy and Radiofrequency Ablation for Chronic Rhinitis: A Systemic Review and Meta-analysis. *Clin. Exp. Otorhinolaryngol.* **2023**, *16*, 369. [CrossRef] [PubMed]
- 22. Scurry, J.P.; Duggan, M.A. Thin layer compared to direct smear in thyroid fine needle aspiration. *Cytopathology* **2000**, *11*, 104–115. [CrossRef]
- 23. Afify, A.M.; Liu, J.; Al-Khafaji, B.M. Cytologic artifacts and pitfalls of thyroid fine-needle aspiration using ThinPrep: A comparative retrospective review. *Cancer* 2001, *93*, 179–186. [CrossRef]
- Cochand-Priollet, B.; Prat, J.J.; Polivka, M.; Thienpont, L.; Dahan, H.; Wassef, M.; Guillausseau, P.J. Thyroid fine needle aspiration: The morphological features on ThinPrep slide preparations. Eighty cases with histological control. *Cytopathology* 2003, 14, 343–349. [CrossRef]
- Cavaliere, A.; Colella, R.; Puxeddu, E.; Gambelunghe, G.; Avenia, N.; d'Ajello, M.; Cartaginese, F.; Vitali, R.; Bellezza, G.; Giansanti, M.; et al. Fine needle aspiration cytology of thyroid nodules: Conventional vs thin layer technique. *J. Endocrinol. Investig.* 2008, 31, 303–308. [CrossRef] [PubMed]
- 26. Jung, C.K.; Lee, A.; Jung, E.S.; Choi, Y.J.; Jung, S.L.; Lee, K.Y. Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration. *Acta Cytol.* **2008**, *52*, 313–319. [CrossRef]
- Luu, M.H.; Fischer, A.H.; Pisharodi, L.; Owens, C.L. Improved preoperative definitive diagnosis of papillary thyroid carcinoma in FNAs prepared with both ThinPrep and conventional smears compared with FNAs prepared with ThinPrep alone. *Cancer Cytopathol.* 2011, 119, 68–73. [CrossRef] [PubMed]
- Koo, J.H.; Lee, S.Y.; Lee, H.-C.; Park, J.-W.; Koong, S.S.; Oh, T.K.; Jeon, H.J.; Kim, E.; Lee, O.-J. CellprepPlus[®] Liquid-based Smear in Sono-guided Thyroid Fine Needle Aspiration: A Comparison of Conventional Method and CellprepPlus[®] Liquid-based Cytology. *Korean J. Pathol.* 2011, 45, 182. [CrossRef]
- 29. Kim, W.; Lee, S.; Ko, Y.; Lim, S.; Kim, W.; Han, H.; Seol, H.; Oh, S.; Moon, W.-J.; Hwang, T. Clinical Usefulness of SurePath[™] Liquid-based Cytology in Thyroid Fine Needle Aspiration: Comparison with the Conventional Smear in Diagnostic Efficacy and Applicability of BRAF Mutation Test. *Korean J. Pathol.* **2011**, *45*, 188. [CrossRef]
- Chang, H.; Lee, E.; Lee, H.; Choi, J.; Kim, A.; Kim, B.H. Comparison of diagnostic values of thyroid aspiration samples using liquid-based preparation and conventional smear: One-year experience in a single institution. *Applies* 2013, 121, 139–145. [CrossRef]
- 31. Nagarajan, N.; Schneider, E.B.; Ali, S.Z.; Zeiger, M.A.; Olson, M.T. How do liquid-based preparations of thyroid fine-needle aspiration compare with conventional smears? An analysis of 5475 specimens. *Thyroid* **2015**, *25*, 308–313. [CrossRef]
- 32. Kumari, M.; Singh, M. A comparison of liquid-based cytology and conventional smears in fine needle aspiration cytology of thyroid lesions: Diagnostic efficacy and pitfalls. *Thyroid Res. Pract.* **2020**, *17*, 14–18. [CrossRef]

- Rufail, M.; Jing, X.; Smola, B.; Heider, A.; Cantley, R.; Pang, J.C.; Lew, M. Comparison of Diagnostic Rates and Concordance with Subsequent Surgical Resections between Conventional Smear and ThinPrep Preparations versus ThinPrep Only in Thyroid Fine Needle Aspiration (T-FNA) Specimens. *Acta Cytol.* 2022, *66*, 36–45. [CrossRef] [PubMed]
- Zhao, J.; Yao, X.; Song, C.; Wang, C. A comparative study of two liquid-based preparation methods: Membrane-based and sedimentation in fine needle aspiration cytology diagnosis in thyroid nodules. *World J. Surg. Oncol.* 2020, 18, 13. [CrossRef] [PubMed]
- Ucak, R.; Eryilmaz, O.T.; Ozguven, B.Y.; Uludag, M.; Kabukcuoğlu, F. Evaluation of Thyroid Fine-Needle Aspiration Biopsies according to Cytological Methods and Comparison with Histopathological Diagnosis. *Şişli Etfal Hastan. Tip Bülteni* 2021, 55, 93–100. [CrossRef]
- 36. Saleh, H.A.; Hammoud, J.; Zakaria, R.; Khan, A.Z. Comparison of Thin-Prep and cell block preparation for the evaluation of Thyroid epithelial lesions on fine needle aspiration biopsy. *Cytojournal* **2008**, *5*, 3. [CrossRef]
- 37. Gupta, S.; Kumar, A.; Verma, R.; Kalra, R.; Gupta, V.; Gill, M.; Sen, R. Comparative Evaluation of Conventional Smear and Liquid Based Cytology in Diagnosis of Thyroid Lesions Using Bethesda System. *J. Cytol. Histol.* **2018**, *9*, 1–6. [CrossRef]
- Mahajan, S.; Rajwanshi, A.; Srinivasan, R.; Radotra, B.; Panda, N. Should Liquid Based Cytology (LBC) be Applied to Thyroid Fine Needle Aspiration Cytology Samples: Comparative Analysis of Conventional and LBC Smears. J. Cytol. 2021, 38, 198. [CrossRef]
- Alam, M.Q.; Pandey, P.; Ralli, M.; Singh Chauhan, J.P.; Aggarwal, R.; Chaturvedi, V.; Kapoor, A.; Trivedi, K.; Agarwal, S. Comparative analysis of cytomorphology of thyroid lesion on conventional cytology versus liquid-based cytology and categorize the lesions according to The Bethesda System for Reporting Thyroid Cytopathology. *J. Cancer Res. Ther.* 2022, *18*, S259–S266. [CrossRef]
- 40. Sayer, A. Comparison of Conventional Smear and Liquid-Based Cytology in Adequacy of Thyroid Fine-Needle Aspiration Biopsies without an Accompanying Cytopathologist. *Med. Bull. Sisli Etfal Hosp.* **2022**, *56*, 353. [CrossRef]
- 41. Kim, D.H.; Kim, M.K.; Chae, S.W.; Lee, K.B.; Han, E.M.; Kang, S.H.; Sohn, J.H. The Usefulness of SurePath Liquid-Based Smear in Sono-Guided Thyroid Fine Needle Aspiration; a Comparison of a Conventional Smear and SurePath Liquid-Based Cytology. *Korean J. Cytopathol.* 2007, *18*, 143–152.
- Reitsma, J.B.; Glas, A.S.; Rutjes, A.W.; Scholten, R.J.; Bossuyt, P.M.; Zwinderman, A.H. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J. Clin. Epidemiol.* 2005, 58, 982–990. [CrossRef] [PubMed]
- 43. Hoeboer, S.H.; van der Geest, P.J.; Nieboer, D.; Groeneveld, A.B. The diagnostic accuracy of procalcitonin for bacteraemia: A systematic review and meta-analysis. *Clin. Microbiol. Infect.* **2015**, *21*, 474–481. [CrossRef] [PubMed]
- Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. *Ann. Intern. Med.* 2011, 155, 529–536. [CrossRef]
- Stamataki, M.; Anninos, D.; Brountzos, E.; Georgoulakis, J.; Panayiotides, J.; Christoni, Z.; Peros, G.; Karakitsos, P. The role of liquid-based cytology in the investigation of thyroid lesions. *Cytopathology* 2008, 19, 11–18. [CrossRef] [PubMed]
- Ardito, G.; Rossi, E.D.; Revelli, L.; Moschella, F.; Giustozzi, E.; Fadda, G.; Marzola, M.C.; Rubello, D. The role of fine-needle aspiration performed with liquid-based cytology in the surgical management of thyroid lesions. *In Vivo* 2010, 24, 333–337. [PubMed]
- 47. Geers, C.; Bourgain, C. Liquid-based FNAC of the thyroid: A 4-year survey with SurePath. *Cancer Cytopathol.* **2011**, *119*, 58–67. [CrossRef] [PubMed]
- Chan, Y.; Paul, A.K.; Kim, N.; Baek, J.H.; Choi, Y.J.; Ha, E.J.; Lee, K.D.; Lee, H.S.; Shin, D.; Kim, N. Computer-aided diagnosis for classifying benign versus malignant thyroid nodules based on ultrasound images: A comparison with radiologist-based assessments. *Med. Phys.* 2016, 43, 554. [CrossRef] [PubMed]
- 49. Erdoğan, B.; Karabağ, A.; Kasap, H.A.; Çivi Çetin, K.; Bal, C.; Şimşek, G. Diagnostic Performance Comparison of Liquid-Based Preparation Methods in Thyroid FNAs. *J. Cytol.* **2023**, *40*, 184–191. [CrossRef]
- 50. Biscotti, C.V.; Hollow, J.A.; Toddy, S.M.; Easley, K.A. ThinPrep versus conventional smear cytologic preparations in the analysis of thyroid fine-needle aspiration specimens. *Am. J. Clin. Pathol.* **1995**, *104*, 150–153. [CrossRef]
- Kim, S.Y.; Kim, E.K.; Moon, H.J.; Yoon, J.H.; Kwon, H.J.; Song, M.K.; Kwak, J.Y. Combined use of conventional smear and liquid-based preparation versus conventional smear for thyroid fine-needle aspiration. *Endocrine* 2016, 53, 157–165. [CrossRef] [PubMed]
- Rossi, E.D.; Raffaelli, M.; Zannoni, G.F.; Pontecorvi, A.; Mulè, A.; Callà, C.; Lombardi, C.P.; Fadda, G. Diagnostic efficacy of conventional as compared to liquid-based cytology in thyroid lesions: Evaluation of 10,360 fine needle aspiration cytology cases. *Acta Cytol.* 2009, 53, 659–666. [CrossRef] [PubMed]
- Frost, A.R.; Sidawy, M.K.; Ferfelli, M.; Tabbara, S.O.; Bronner, N.A.; Brosky, K.R.; Sherman, M.E. Utility of thin-layer preparations in thyroid fine-needle aspiration: Diagnostic accuracy, cytomorphology, and optimal sample preparation. *Cancer* 1998, 84, 17–25. [CrossRef]
- O'Malley, M.E.; Weir, M.M.; Hahn, P.F.; Misdraji, J.; Wood, B.J.; Mueller, P.R. US-guided fine-needle aspiration biopsy of thyroid nodules: Adequacy of cytologic material and procedure time with and without immediate cytologic analysis. *Radiology* 2002, 222, 383–387. [CrossRef] [PubMed]

- 55. Chong, Y.; Baek, K.H.; Kim, J.Y.; Kim, T.J.; Lee, E.J.; Kang, C.S. Comparison of EASYPREP([®]) and SurePath([®]) in thyroid fine-needle aspiration. *Diagn. Cytopathol.* **2016**, *44*, 283–290. [CrossRef]
- 56. Sharma, R.; Zaheer, S.; Ahluwalia, C. Diagnostic utility of conventional and liquid-based cytology in the management of thyroid lesions; an institutional experience. *Cytojournal* **2022**, *19*, 36. [CrossRef]
- 57. Szporn, A.H.; Yuan, S.; Wu, M.; Burstein, D.E. Cellular swirls in fine needle aspirates of papillary thyroid carcinoma: A new diagnostic criterion. *Mod. Pathol.* 2006, *19*, 1470–1473. [CrossRef]
- 58. Xiao, M.M.; Zhao, Y.B.; Liu, D.G.; Qiu, X.S.; Wang, E.H.; Wu, G.P. The Morphological Analysis of Cells in the Bronchoscopic Brushing and TBNA of Patients with Lung Adenocarcinoma. *Cell Transplant.* **2020**, *29*, 963689720923599. [CrossRef]
- 59. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016, *26*, 1–133. [CrossRef]
- Rossi, E.D.; Martini, M.; Capodimonti, S.; Lombardi, C.P.; Pontecorvi, A.; Vellone, V.G.; Zannoni, G.F.; Larocca, L.M.; Fadda, G. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. *Cancer Cytopathol.* 2013, 121, 291–297. [CrossRef]
- Davey, E.; Barratt, A.; Irwig, L.; Chan, S.F.; Macaskill, P.; Mannes, P.; Saville, A.M. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: A systematic review. *Lancet* 2006, 367, 122–132. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.